1
|
Petitjean K, Verres Y, Bristeau S, Ribault C, Aninat C, Olivier C, Leroyer P, Ropert M, Loréal O, Herault O, Amalric L, Baran N, Fromenty B, Corlu A, Loyer P. Low concentrations of ethylene bisdithiocarbamate pesticides maneb and mancozeb impair manganese and zinc homeostasis to induce oxidative stress and caspase-dependent apoptosis in human hepatocytes. Chemosphere 2024; 346:140535. [PMID: 37923018 DOI: 10.1016/j.chemosphere.2023.140535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Revised: 10/02/2023] [Accepted: 10/23/2023] [Indexed: 11/07/2023]
Abstract
The worldwide and intensive use of phytosanitary compounds results in environmental and food contamination by chemical residues. Human exposure to multiple pesticide residues is a major health issue. Considering that the liver is not only the main organ for metabolizing pesticides but also a major target of toxicities induced by xenobiotics, we studied the effects of a mixture of 7 pesticides (chlorpyrifos-ethyl, dimethoate, diazinon, iprodione, imazalil, maneb, mancozeb) often detected in food samples. Effects of the mixture was investigated using metabolically competent HepaRG cells and human hepatocytes in primary culture. We report the strong cytotoxicity of the pesticide mixture towards hepatocytes-like HepaRG cells and human hepatocytes upon acute and chronic exposures at low concentrations extrapolated from the Acceptable Daily Intake (ADI) of each compound. Unexpectedly, we demonstrated that the manganese (Mn)-containing dithiocarbamates (DTCs) maneb and mancozeb were solely responsible for the cytotoxicity induced by the mixture. The mechanism of cell death involved the induction of oxidative stress, which led to cell death by intrinsic apoptosis involving caspases 3 and 9. Importantly, this cytotoxic effect was found only in cells metabolizing these pesticides. Herein, we unveil a novel mechanism of toxicity of the Mn-containing DTCs maneb and mancozeb through their metabolization in hepatocytes generating the main metabolite ethylene thiourea (ETU) and the release of Mn leading to intracellular Mn overload and depletion in zinc (Zn). Alteration of the Mn and Zn homeostasis provokes the oxidative stress and the induction of apoptosis, which can be prevented by Zn supplementation. Our data demonstrate the hepatotoxicity of Mn-containing fungicides at very low doses and unveil their adverse effect in disrupting Mn and Zn homeostasis and triggering oxidative stress in human hepatocytes.
Collapse
Affiliation(s)
- Kilian Petitjean
- Inserm, INRAE, Univ Rennes, Institut NUMECAN (Nutrition Métabolismes et Cancer) UMR-A 1341, UMR-S 1317, F-35000 Rennes, France
| | - Yann Verres
- Inserm, INRAE, Univ Rennes, Institut NUMECAN (Nutrition Métabolismes et Cancer) UMR-A 1341, UMR-S 1317, F-35000 Rennes, France
| | - Sébastien Bristeau
- BRGM, Direction Eau, Environnement, Procédés et Analyses (DEPA), 3 Avenue Claude-Guillemin - BP 36009, 45060 Orléans Cedex 2, France
| | - Catherine Ribault
- Inserm, INRAE, Univ Rennes, Institut NUMECAN (Nutrition Métabolismes et Cancer) UMR-A 1341, UMR-S 1317, F-35000 Rennes, France
| | - Caroline Aninat
- Inserm, INRAE, Univ Rennes, Institut NUMECAN (Nutrition Métabolismes et Cancer) UMR-A 1341, UMR-S 1317, F-35000 Rennes, France
| | - Christophe Olivier
- Cancéropole Grand Ouest (CGO), NET "Niches and Epigenetics of Tumors" Network, 44000 Nantes, France; INSERM UMR 1232 CRCINA, 44000 Nantes-Angers, France; Faculty of Pharmaceutical and Biological Sciences, Nantes University, 44000 Nantes, France
| | - Patricia Leroyer
- Inserm, INRAE, Univ Rennes, Institut NUMECAN (Nutrition Métabolismes et Cancer) UMR-A 1341, UMR-S 1317, F-35000 Rennes, France
| | - Martine Ropert
- Inserm, INRAE, Univ Rennes, Institut NUMECAN (Nutrition Métabolismes et Cancer) UMR-A 1341, UMR-S 1317, F-35000 Rennes, France; AEM2 Platform, CHU Pontchaillou, 2 Rue Henri le Guilloux, 35033 Rennes, France
| | - Olivier Loréal
- Inserm, INRAE, Univ Rennes, Institut NUMECAN (Nutrition Métabolismes et Cancer) UMR-A 1341, UMR-S 1317, F-35000 Rennes, France
| | - Olivier Herault
- Cancéropole Grand Ouest (CGO), NET "Niches and Epigenetics of Tumors" Network, 44000 Nantes, France; Department of Biological Hematology, Tours University Hospital, 37000 Tours, France; CNRS ERL 7001 LNOx, EA 7501, Tours University, 37000 Tours, France; CNRS GDR3697 Micronit "Microenvironment of Tumor Niches", Tours, France
| | - Laurence Amalric
- BRGM, Direction Eau, Environnement, Procédés et Analyses (DEPA), 3 Avenue Claude-Guillemin - BP 36009, 45060 Orléans Cedex 2, France
| | - Nicole Baran
- BRGM, Direction Eau, Environnement, Procédés et Analyses (DEPA), 3 Avenue Claude-Guillemin - BP 36009, 45060 Orléans Cedex 2, France
| | - Bernard Fromenty
- Inserm, INRAE, Univ Rennes, Institut NUMECAN (Nutrition Métabolismes et Cancer) UMR-A 1341, UMR-S 1317, F-35000 Rennes, France
| | - Anne Corlu
- Inserm, INRAE, Univ Rennes, Institut NUMECAN (Nutrition Métabolismes et Cancer) UMR-A 1341, UMR-S 1317, F-35000 Rennes, France; Cancéropole Grand Ouest (CGO), NET "Niches and Epigenetics of Tumors" Network, 44000 Nantes, France.
| | - Pascal Loyer
- Inserm, INRAE, Univ Rennes, Institut NUMECAN (Nutrition Métabolismes et Cancer) UMR-A 1341, UMR-S 1317, F-35000 Rennes, France; Cancéropole Grand Ouest (CGO), NET "Niches and Epigenetics of Tumors" Network, 44000 Nantes, France.
| |
Collapse
|
2
|
Lejeune J, Raoult V, Dubrasquet M, Chauvin R, Mallebranche C, Pellier I, Monceaux F, Bayart S, Grain A, Gyan E, Ravalet N, Herault O, Ternant D. Prediction of the Clinical Course of Immune Thrombocytopenia in Children by Platelet Kinetics. Hemasphere 2023; 7:e960. [PMID: 37908859 PMCID: PMC10615561 DOI: 10.1097/hs9.0000000000000960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Accepted: 08/16/2023] [Indexed: 11/02/2023] Open
Abstract
Childhood immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by isolated thrombocytopenia. Prolonged ITP (persistent and chronic) leads to a reduced quality of life for children in many domains. To provide optimal support for children, with ITP, it is important to be able to predict those who will develop prolonged ITP. This study aimed to develop a mathematical model based on platelet recovery that allows the early prediction of prolonged ITP. In this retrospective study, we used platelet counts from the 6 months following the diagnosis of ITP to model the kinetics of change in platelet count using a pharmacokinetic-pharmacodynamic model. In a learning set (n = 103), platelet counts were satisfactorily described by our kinetic model. The Kheal parameter, which describes spontaneous platelet recovery, allowed a distinction between acute and prolonged ITP with an area under the curve (AUC) of 0.74. In a validation set (n = 58), spontaneous platelet recovery was robustly predicted using platelet counts from 15 (AUC = 0.76) or 30 (AUC = 0.82) days after ITP diagnosis. In our model, platelet recovery quantified using the kheal parameter allowed prediction of the clinical course of ITP. Future prospective studies are needed to improve the predictivity of this model, in particular, by combining it with the predictive scores previously reported in the literature.
Collapse
Affiliation(s)
- Julien Lejeune
- Pediatric Onco-Hematology Unit, CHU de Tours, France
- CNRS ERL7001, EA 7501 GICC, University of Tours, France
| | | | | | | | | | | | | | - Sophie Bayart
- Pediatric and Adolescent Unit, CHRU de Rennes, France
| | - Audrey Grain
- Pediatric Immuno-Hemato-Oncology Unit, CHU Nantes, France
| | - Emmanuel Gyan
- Pediatric Onco-Hematology Unit, CHU de Tours, France
- CNRS ERL7001, EA 7501 GICC, University of Tours, France
| | - Noémie Ravalet
- CNRS ERL7001, EA 7501 GICC, University of Tours, France
- Department of Biological Hematology, Tours University Hospital, Tours, France
| | - Olivier Herault
- CNRS ERL7001, EA 7501 GICC, University of Tours, France
- Department of Biological Hematology, Tours University Hospital, Tours, France
| | - David Ternant
- EA 7501 « Transplantation, Immunology, Inflammation », University of Tours, France
| |
Collapse
|
3
|
Ravalet N, Guermouche H, Hirsch P, Picou F, Foucault A, Gallay N, Martignoles JA, Beaud J, Suner L, Deswarte C, Lachot S, Rault E, Largeaud L, Gissot V, Béné MC, Gyan E, Delhommeau F, Herault O. Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals. Clin Immunol 2023; 255:109730. [PMID: 37562724 DOI: 10.1016/j.clim.2023.109730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Revised: 07/10/2023] [Accepted: 07/20/2023] [Indexed: 08/12/2023]
Abstract
Aging is associated with bone marrow (BM) inflammaging and, in some individuals, with the onset of clonal hematopoiesis (CH) of indeterminate potential. In this study conducted on 94 strictly healthy volunteers (18 to 80 yo), we measured BM and peripheral blood (PB) plasma levels of 49 hematopoietic and inflammatory cytokines. With aging, 7 cytokines increased in BM (FLT3L, CXCL9, HGF, FGF-2, CCL27, IL-16, IL-18) and 8 decreased (G-CSF, TNF, IL-2, IL-15, IL-17A, CCL7, IL-4, IL-10). In PB, 10 cytokines increased with age (CXCL9, FLT3L, CCL27, CXCL10, HGF, CCL11, IL-16, IL-6, IL-1 beta, CCL2). CH was associated with higher BM levels of MIF and IL-1 beta, lower BM levels of IL-9 and IL-5 and higher PB levels of IL-15, VEGF-A, IL-2, CXCL8, CXCL1 and G-CSF. These reference values provide a useful tool to investigate anomalies related to inflammaging and potentially leading to the onset of age-related myeloid malignancies or inflammatory conditions.
Collapse
Affiliation(s)
- Noémie Ravalet
- CNRS EMR 7001 LNOx "Leukemic niche and redox metabolism", EA7501 GICC, Tours, France; Tours University Hospital, Department of Biological Hematology, Tours, France
| | - Hélène Guermouche
- Sorbonne University, INSERM, Saint-Antoine Research Center, CRSA, AP-HP, Saint-Antoine Hospital, Paris, France
| | - Pierre Hirsch
- Sorbonne University, INSERM, Saint-Antoine Research Center, CRSA, AP-HP, Saint-Antoine Hospital, Paris, France
| | - Frédéric Picou
- CNRS EMR 7001 LNOx "Leukemic niche and redox metabolism", EA7501 GICC, Tours, France; Tours University Hospital, Department of Biological Hematology, Tours, France
| | - Amélie Foucault
- CNRS EMR 7001 LNOx "Leukemic niche and redox metabolism", EA7501 GICC, Tours, France; Tours University Hospital, Department of Biological Hematology, Tours, France
| | - Nathalie Gallay
- CNRS EMR 7001 LNOx "Leukemic niche and redox metabolism", EA7501 GICC, Tours, France; Tours University Hospital, Department of Biological Hematology, Tours, France
| | - Jean-Alain Martignoles
- Sorbonne University, INSERM, Saint-Antoine Research Center, CRSA, AP-HP, Saint-Antoine Hospital, Paris, France
| | - Jenny Beaud
- Sorbonne University, INSERM, Saint-Antoine Research Center, CRSA, AP-HP, Saint-Antoine Hospital, Paris, France
| | - Ludovic Suner
- Sorbonne University, INSERM, Saint-Antoine Research Center, CRSA, AP-HP, Saint-Antoine Hospital, Paris, France
| | - Caroline Deswarte
- Sorbonne University, INSERM, Saint-Antoine Research Center, CRSA, AP-HP, Saint-Antoine Hospital, Paris, France
| | - Sébastien Lachot
- Tours University Hospital, Department of Biological Hematology, Tours, France
| | - Emmanuelle Rault
- Tours University Hospital, Department of Biological Hematology, Tours, France
| | - Laëtitia Largeaud
- Sorbonne University, INSERM, Saint-Antoine Research Center, CRSA, AP-HP, Saint-Antoine Hospital, Paris, France
| | - Valérie Gissot
- INSERM CIC 1415, Tours University Hospital, Tours, France
| | - Marie-Christine Béné
- Nantes University Hospital, Hematology Biology and INSERM CRCI2NA, Nantes, France; FHU GOAL "Grand Ouest Against Leukemia", Angers, France
| | - Emmanuel Gyan
- CNRS EMR 7001 LNOx "Leukemic niche and redox metabolism", EA7501 GICC, Tours, France; Tours University Hospital, Department of Hematology and Cell Therapy, Tours, France
| | - François Delhommeau
- Sorbonne University, INSERM, Saint-Antoine Research Center, CRSA, AP-HP, Saint-Antoine Hospital, Paris, France; OPALE Carnot Institute, Paris, France; CNRS GDR3697 Micronit "Microenvironment of tumor niches", Tours, France.
| | - Olivier Herault
- CNRS EMR 7001 LNOx "Leukemic niche and redox metabolism", EA7501 GICC, Tours, France; Tours University Hospital, Department of Biological Hematology, Tours, France; FHU GOAL "Grand Ouest Against Leukemia", Angers, France; OPALE Carnot Institute, Paris, France; CNRS GDR3697 Micronit "Microenvironment of tumor niches", Tours, France.
| |
Collapse
|
4
|
Lanznaster D, Bruno C, Bourgeais J, Emond P, Zemmoura I, Lefèvre A, Reynier P, Eymieux S, Blanchard E, Vourc’h P, Andres CR, Bakkouche SE, Herault O, Favard L, Corcia P, Blasco H. Metabolic Profile and Pathological Alterations in the Muscle of Patients with Early-Stage Amyotrophic Lateral Sclerosis. Biomedicines 2022; 10:biomedicines10061307. [PMID: 35740329 PMCID: PMC9220134 DOI: 10.3390/biomedicines10061307] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Revised: 05/30/2022] [Accepted: 05/30/2022] [Indexed: 12/26/2022] Open
Abstract
Diverse biomarkers and pathological alterations have been found in muscle of patients with Amyotrophic lateral sclerosis (ALS), but the relation between such alterations and dysfunction in energetic metabolism remains to be investigated. We established the metabolome of muscle and serum of ALS patients and correlated these findings with the clinical status and pathological alterations observed in the muscle. We obtained data from 20 controls and 17 ALS patients (disease duration: 9.4 ± 6.8 months). Multivariate metabolomics analysis identified a distinct serum metabolome for ALS compared to controls (p-CV-ANOVA < 0.035) and revealed an excellent discriminant profile for muscle metabolome (p-CV-ANOVA < 0.0012). Citramalate was discriminant for both muscle and serum. High lauroylcarnitine levels in muscle were associated with low Forced Vital Capacity. Transcriptomics analysis of key antioxidant enzymes showed an upregulation of SOD3 (p = 0.0017) and GLRX2(1) (p = 0.0022) in ALS muscle. Analysis of mitochondrial enzymatic activity in muscle revealed higher complex II/CS (p = 0.04) and lower LDH (p = 0.03) activity in ALS than in controls. Our study showed, for the first time, a global dysfunction in the muscle of early-stage ALS patients. Furthermore, we identified novel metabolites to be employed as biomarkers for diagnosis and prognosis of ALS patients.
Collapse
Affiliation(s)
- Débora Lanznaster
- UMR 1253, iBrain, Université de Tours, INSERM, 37000 Tours, France; (C.B.); (P.E.); (I.Z.); (A.L.); (P.V.); (C.R.A.); (P.C.); (H.B.)
- Correspondence:
| | - Clément Bruno
- UMR 1253, iBrain, Université de Tours, INSERM, 37000 Tours, France; (C.B.); (P.E.); (I.Z.); (A.L.); (P.V.); (C.R.A.); (P.C.); (H.B.)
- Service de Biochimie et Biologie Moléculaire, CHU de Tours, 37000 Tours, France
| | - Jérôme Bourgeais
- CNRS ERL7001, EA 7501 GICC, Université de Tours, 37000 Tours, France; (J.B.); (O.H.)
| | - Patrick Emond
- UMR 1253, iBrain, Université de Tours, INSERM, 37000 Tours, France; (C.B.); (P.E.); (I.Z.); (A.L.); (P.V.); (C.R.A.); (P.C.); (H.B.)
- Service de Médecine Nucléaire In Vitro, CHU de Tours, 37000 Tours, France
| | - Ilyess Zemmoura
- UMR 1253, iBrain, Université de Tours, INSERM, 37000 Tours, France; (C.B.); (P.E.); (I.Z.); (A.L.); (P.V.); (C.R.A.); (P.C.); (H.B.)
- Service de Neurochirurgie, CHU de Tours, 37000 Tours, France
| | - Antoine Lefèvre
- UMR 1253, iBrain, Université de Tours, INSERM, 37000 Tours, France; (C.B.); (P.E.); (I.Z.); (A.L.); (P.V.); (C.R.A.); (P.C.); (H.B.)
| | - Pascal Reynier
- Service de Biochimie et Biologie Moléculaire, CHU d’Angers, 49000 Angers, France;
- Mitovasc-Mitolab, UMR CNRS6015-INSERM1083, 49000 Angers, France
| | - Sébastien Eymieux
- Plateforme IBiSA de Microscopie Electronique, Université de Tours et CHU de Tours, 37000 Tours, France; (S.E.); (E.B.)
- INSERM U1259, Université de Tours, 37000 Tours, France
| | - Emmanuelle Blanchard
- Plateforme IBiSA de Microscopie Electronique, Université de Tours et CHU de Tours, 37000 Tours, France; (S.E.); (E.B.)
- INSERM U1259, Université de Tours, 37000 Tours, France
| | - Patrick Vourc’h
- UMR 1253, iBrain, Université de Tours, INSERM, 37000 Tours, France; (C.B.); (P.E.); (I.Z.); (A.L.); (P.V.); (C.R.A.); (P.C.); (H.B.)
- Service de Biochimie et Biologie Moléculaire, CHU de Tours, 37000 Tours, France
| | - Christian R. Andres
- UMR 1253, iBrain, Université de Tours, INSERM, 37000 Tours, France; (C.B.); (P.E.); (I.Z.); (A.L.); (P.V.); (C.R.A.); (P.C.); (H.B.)
- Service de Biochimie et Biologie Moléculaire, CHU de Tours, 37000 Tours, France
| | | | - Olivier Herault
- CNRS ERL7001, EA 7501 GICC, Université de Tours, 37000 Tours, France; (J.B.); (O.H.)
| | - Luc Favard
- Service de Neurologie, CHU de Tours, 37000 Tours, France;
| | - Philippe Corcia
- UMR 1253, iBrain, Université de Tours, INSERM, 37000 Tours, France; (C.B.); (P.E.); (I.Z.); (A.L.); (P.V.); (C.R.A.); (P.C.); (H.B.)
- Service de Neurologie, CHU de Tours, 37000 Tours, France;
| | - Hélène Blasco
- UMR 1253, iBrain, Université de Tours, INSERM, 37000 Tours, France; (C.B.); (P.E.); (I.Z.); (A.L.); (P.V.); (C.R.A.); (P.C.); (H.B.)
- Service de Biochimie et Biologie Moléculaire, CHU de Tours, 37000 Tours, France
| |
Collapse
|
5
|
Dakik H, El Dor M, Bourgeais J, Kouzi F, Herault O, Gouilleux F, Zibara K, Mazurier F. Diphenyleneiodonium Triggers Cell Death of Acute Myeloid Leukemia Cells by Blocking the Mitochondrial Respiratory Chain, and Synergizes with Cytarabine. Cancers (Basel) 2022; 14:cancers14102485. [PMID: 35626090 PMCID: PMC9140039 DOI: 10.3390/cancers14102485] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Revised: 05/09/2022] [Accepted: 05/11/2022] [Indexed: 12/19/2022] Open
Abstract
Simple Summary Acute myeloid leukemia (AML) is an aggressive heterogeneous cancer of the blood, of which 70% of cases develop relapse. Relapse is mainly due to chemoresistant leukemic cells (LCs) that are characterized by high mitochondrial oxidative phosphorylation (OxPhos) status, i.e., cells that are dependent on the mitochondrial respiratory chain (MRC) function. The aim of our study was to determine whether diphenyleneiodonium (DPI)—known as a potent inhibitor of flavoproteins—could be used to target AML cells. Herein, we demonstrate that DPI disrupts the mitochondrial function of AML cell lines. Interestingly, we found that cells with high OxPhos are more sensitive to the apoptotic effects of DPI. Moreover, we showed that DPI sensitizes AML cell lines to cytarabine (Ara-C) treatment, suggesting that MRC inhibitors could be employed to target LCs that are resistant to this chemotherapeutic agent. Abstract Acute myeloid leukemia (AML) is characterized by the accumulation of undifferentiated blast cells in the bone marrow and blood. In most cases of AML, relapse frequently occurs due to resistance to chemotherapy. Compelling research results indicate that drug resistance in cancer cells is highly dependent on the intracellular levels of reactive oxygen species (ROS). Modulating ROS levels is therefore a valuable strategy to overcome the chemotherapy resistance of leukemic cells. In this study, we evaluated the efficiency of diphenyleneiodonium (DPI)—a well-known inhibitor of ROS production—in targeting AML cells. Results showed that although inhibiting cytoplasmic ROS production, DPI also triggered an increase in the mitochondrial ROS levels, caused by the disruption of the mitochondrial respiratory chain. We also demonstrated that DPI blocks mitochondrial oxidative phosphorylation (OxPhos) in a dose-dependent manner, and that AML cells with high OxPhos status are highly sensitive to treatment with DPI, which synergizes with the chemotherapeutic agent cytarabine (Ara-C). Thus, our results suggest that targeting mitochondrial function with DPI might be exploited to target AML cells with high OxPhos status.
Collapse
Affiliation(s)
- Hassan Dakik
- EA7501 GICC/CNRS ERL7001 LNOx, University of Tours, F-37032 Tours, France; (H.D.); (M.E.D.); (J.B.); (F.K.); (O.H.); (F.G.)
| | - Maya El Dor
- EA7501 GICC/CNRS ERL7001 LNOx, University of Tours, F-37032 Tours, France; (H.D.); (M.E.D.); (J.B.); (F.K.); (O.H.); (F.G.)
| | - Jérôme Bourgeais
- EA7501 GICC/CNRS ERL7001 LNOx, University of Tours, F-37032 Tours, France; (H.D.); (M.E.D.); (J.B.); (F.K.); (O.H.); (F.G.)
- Department of Biological Hematology, Tours University Hospital, F-37000 Tours, France
| | - Farah Kouzi
- EA7501 GICC/CNRS ERL7001 LNOx, University of Tours, F-37032 Tours, France; (H.D.); (M.E.D.); (J.B.); (F.K.); (O.H.); (F.G.)
- Biology Department, Faculty of Sciences, Lebanese University, Beirut 90656, Lebanon
| | - Olivier Herault
- EA7501 GICC/CNRS ERL7001 LNOx, University of Tours, F-37032 Tours, France; (H.D.); (M.E.D.); (J.B.); (F.K.); (O.H.); (F.G.)
- Department of Biological Hematology, Tours University Hospital, F-37000 Tours, France
| | - Fabrice Gouilleux
- EA7501 GICC/CNRS ERL7001 LNOx, University of Tours, F-37032 Tours, France; (H.D.); (M.E.D.); (J.B.); (F.K.); (O.H.); (F.G.)
| | - Kazem Zibara
- Biology Department, Faculty of Sciences, Lebanese University, Beirut 90656, Lebanon
- ER045, PRASE, Beirut 6573/14, Lebanon
- Correspondence: (K.Z.); (F.M.)
| | - Frédéric Mazurier
- EA7501 GICC/CNRS ERL7001 LNOx, University of Tours, F-37032 Tours, France; (H.D.); (M.E.D.); (J.B.); (F.K.); (O.H.); (F.G.)
- Correspondence: (K.Z.); (F.M.)
| |
Collapse
|
6
|
Guillon A, Brea-Diakite D, Cezard A, Wacquiez A, Baranek T, Bourgeais J, Picou F, Vasseur V, Meyer L, Chevalier C, Auvet A, Carballido JM, Nadal Desbarats L, Dingli F, Turtoi A, Le Gouellec A, Fauvelle F, Donchet A, Crépin T, Hiemstra PS, Paget C, Loew D, Herault O, Naffakh N, Le Goffic R, Si-Tahar M. Host succinate inhibits influenza virus infection through succinylation and nuclear retention of the viral nucleoprotein. EMBO J 2022; 41:e108306. [PMID: 35506364 PMCID: PMC9194747 DOI: 10.15252/embj.2021108306] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Revised: 04/03/2022] [Accepted: 04/04/2022] [Indexed: 12/11/2022] Open
Abstract
Influenza virus infection causes considerable morbidity and mortality, but current therapies have limited efficacy. We hypothesized that investigating the metabolic signaling during infection may help to design innovative antiviral approaches. Using bronchoalveolar lavages of infected mice, we here demonstrate that influenza virus induces a major reprogramming of lung metabolism. We focused on mitochondria‐derived succinate that accumulated both in the respiratory fluids of virus‐challenged mice and of patients with influenza pneumonia. Notably, succinate displays a potent antiviral activity in vitro as it inhibits the multiplication of influenza A/H1N1 and A/H3N2 strains and strongly decreases virus‐triggered metabolic perturbations and inflammatory responses. Moreover, mice receiving succinate intranasally showed reduced viral loads in lungs and increased survival compared to control animals. The antiviral mechanism involves a succinate‐dependent posttranslational modification, that is, succinylation, of the viral nucleoprotein at the highly conserved K87 residue. Succinylation of viral nucleoprotein altered its electrostatic interactions with viral RNA and further impaired the trafficking of viral ribonucleoprotein complexes. The finding that succinate efficiently disrupts the influenza replication cycle opens up new avenues for improved treatment of influenza pneumonia.
Collapse
Affiliation(s)
- Antoine Guillon
- INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, Tours, France.,Université de Tours, Tours, France.,Service de Médecine Intensive Réanimation, CHRU de Tours, Tours, France
| | - Deborah Brea-Diakite
- INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, Tours, France.,Université de Tours, Tours, France
| | - Adeline Cezard
- INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, Tours, France.,Université de Tours, Tours, France
| | - Alan Wacquiez
- INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, Tours, France.,Université de Tours, Tours, France
| | - Thomas Baranek
- INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, Tours, France.,Université de Tours, Tours, France
| | - Jérôme Bourgeais
- Université de Tours, Tours, France.,CNRS ERL 7001 LNOx "Leukemic niche and redox metabolism", Tours, France.,Service d'Hématologie Biologique, CHRU de Tours, Tours, France
| | - Frédéric Picou
- Université de Tours, Tours, France.,CNRS ERL 7001 LNOx "Leukemic niche and redox metabolism", Tours, France.,Service d'Hématologie Biologique, CHRU de Tours, Tours, France
| | - Virginie Vasseur
- INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, Tours, France.,Université de Tours, Tours, France
| | - Léa Meyer
- Virologie et Immunologie Moléculaires, INRAe, Université Paris-Saclay, Jouy-en-Josas, France
| | - Christophe Chevalier
- Virologie et Immunologie Moléculaires, INRAe, Université Paris-Saclay, Jouy-en-Josas, France
| | - Adrien Auvet
- INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, Tours, France.,Université de Tours, Tours, France.,Service de Médecine Intensive Réanimation, CHRU de Tours, Tours, France
| | | | | | - Florent Dingli
- Centre de Recherche, Laboratoire de Spectrométrie de Masse Protéomique, Institut Curie, PSL Research University, Paris, France
| | - Andrei Turtoi
- Tumor Microenvironment Laboratory, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier, France.,Institut du Cancer de Montpellier, Montpellier, France.,Université de Montpellier, Montpellier, France
| | - Audrey Le Gouellec
- CNRS, CHU Grenoble Alpes, Grenoble INP, TIMC-IMAG, University Grenoble Alpes, Grenoble, France
| | - Florence Fauvelle
- UGA/INSERM U1216, Grenoble Institute of Neurosciences, Grenoble, France.,UGA/INSERM US17, Grenoble MRI Facility IRMaGe, Grenoble, France
| | - Amélie Donchet
- Institut de Biologie Structurale (IBS), CEA, CNRS, University Grenoble Alpes, Grenoble, France
| | - Thibaut Crépin
- Institut de Biologie Structurale (IBS), CEA, CNRS, University Grenoble Alpes, Grenoble, France
| | - Pieter S Hiemstra
- Department of Pulmonology, Leiden University Medical Center, Leiden, Netherlands
| | - Christophe Paget
- INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, Tours, France.,Université de Tours, Tours, France
| | - Damarys Loew
- Centre de Recherche, Laboratoire de Spectrométrie de Masse Protéomique, Institut Curie, PSL Research University, Paris, France
| | - Olivier Herault
- Université de Tours, Tours, France.,CNRS ERL 7001 LNOx "Leukemic niche and redox metabolism", Tours, France.,Service d'Hématologie Biologique, CHRU de Tours, Tours, France
| | - Nadia Naffakh
- Institut Pasteur, Unité Biologie des ARN et Virus Influenza, CNRS UMR3569, Paris, France
| | - Ronan Le Goffic
- Virologie et Immunologie Moléculaires, INRAe, Université Paris-Saclay, Jouy-en-Josas, France
| | - Mustapha Si-Tahar
- INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, Tours, France.,Université de Tours, Tours, France
| |
Collapse
|
7
|
Potier-Cartereau M, Gautier M, Ravalet N, Ducrocq E, Hamard S, LeGuennec JY, Vandier C, Herault O. The Sodium–Calcium Exchanger Controls the Membrane Potential of AFT024: A Mesenchymal Stem Cell Hematopoietic Niche Forming Line. Bioelectricity 2022. [DOI: 10.1089/bioe.2022.0015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - Mathieu Gautier
- LPCM UR 4667, University of Picardie Jules Verne, Amiens, France
| | - Noemie Ravalet
- LNOx EMR 7001/EA 7501, University of Tours, CNRS, Tours, France
| | - Elfi Ducrocq
- LNOx EMR 7001/EA 7501, University of Tours, CNRS, Tours, France
| | - Sophie Hamard
- LNOx EMR 7001/EA 7501, University of Tours, CNRS, Tours, France
| | - Jean-Yves LeGuennec
- UMR 01046–UMR 9214, University of Montpellier, INSERM, CNRS, Montpellier, France
| | | | - Olivier Herault
- LNOx EMR 7001/EA 7501, University of Tours, CNRS, Tours, France
- Department of Biological Hematology, Tours University Hospital, Tours, France
- OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France
| |
Collapse
|
8
|
Roux B, Picou F, Debeissat C, Koubi M, Gallay N, Hirsch P, Ravalet N, Béné MC, Maigre M, Hunault M, Mosser J, Etcheverry A, Gyan E, Delhommeau F, Domenech J, Herault O. Aberrant DNA methylation impacts HOX genes expression in bone marrow mesenchymal stromal cells of myelodysplastic syndromes and de novo acute myeloid leukemia. Cancer Gene Ther 2022; 29:1263-1275. [PMID: 35194200 DOI: 10.1038/s41417-022-00441-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2021] [Revised: 12/12/2021] [Accepted: 02/08/2022] [Indexed: 11/09/2022]
Abstract
DNA methylation, a major biological process regulating the transcription, contributes to the pathophysiology of hematologic malignancies, and hypomethylating agents are commonly used to treat myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML). In these diseases, bone marrow mesenchymal stromal cells (MSCs) play a key supportive role through the production of various signals and interactions. The DNA methylation status of MSCs, likely to reflect their functionality, might be relevant to understand their contribution to the pathophysiology of these diseases. Consequently, the aim of our study was to analyze the modifications of DNA methylation profiles of MSCs induced by MDS or AML. MSCs from MDS/AML patients were characterized via 5-methylcytosine quantification, gene expression profiles of key regulators of DNA methylation, identification of differentially methylated regions (DMRs) by methylome array, and quantification of DMR-coupled genes expression. MDS and AML-MSCs displayed global hypomethylation and under-expression of DNMT1 and UHRF1. Methylome analysis revealed aberrant methylation profiles in all MDS and in a subgroup of AML-MSCs. This aberrant methylation was preferentially found in the sequence of homeobox genes, especially from the HOX family (HOXA1, HOXA4, HOXA5, HOXA9, HOXA10, HOXA11, HOXB5, HOXC4, and HOXC6), and impacted on their expression. These results highlight modifications of DNA methylation in MDS/AML-MSCs, both at global and focal levels dysregulating the expression of HOX genes well known for their involvement in leukemogenesis. Such DNA methylation in MSCs could be the consequence of the malignant disease or could participate in its development through defective functionality or exosomal transfer of HOX transcription factors from MSCs to hematopoietic cells.
Collapse
Affiliation(s)
- Benjamin Roux
- CNRS EMR 7001 LNOx "Leukemic niche & redox metabolism", Tours, France.,EA 7501 GICC, université de Tours, Tours, France.,CHU de Tours, Service d'Hématologie Biologique, Tours, France
| | - Frédéric Picou
- CNRS EMR 7001 LNOx "Leukemic niche & redox metabolism", Tours, France.,EA 7501 GICC, université de Tours, Tours, France.,CHU de Tours, Service d'Hématologie Biologique, Tours, France
| | - Christelle Debeissat
- CNRS EMR 7001 LNOx "Leukemic niche & redox metabolism", Tours, France.,EA 7501 GICC, université de Tours, Tours, France.,CHU de Tours, Service d'Hématologie Biologique, Tours, France
| | - Myriam Koubi
- CNRS EMR 7001 LNOx "Leukemic niche & redox metabolism", Tours, France.,EA 7501 GICC, université de Tours, Tours, France
| | - Nathalie Gallay
- CNRS EMR 7001 LNOx "Leukemic niche & redox metabolism", Tours, France.,EA 7501 GICC, université de Tours, Tours, France.,CHU de Tours, Service d'Hématologie Biologique, Tours, France
| | - Pierre Hirsch
- Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hôpital Saint-Antoine, Service d'Hématologie Biologique, Paris, France
| | - Noémie Ravalet
- CNRS EMR 7001 LNOx "Leukemic niche & redox metabolism", Tours, France.,EA 7501 GICC, université de Tours, Tours, France.,CHU de Tours, Service d'Hématologie Biologique, Tours, France
| | - Marie C Béné
- CHU de Nantes, Service d'Hématologie Biologique, CRCINA, Nantes, France.,FHU GOAL, Angers, France
| | | | - Mathilde Hunault
- FHU GOAL, Angers, France.,CHU d'Angers, Service d'Hématologie, Angers, France
| | - Jean Mosser
- CHU de Rennes, Service de Génétique Moléculaire et Génomique, Rennes, France.,Cancéropôle Grand Ouest, Nantes, France
| | - Amandine Etcheverry
- CHU de Rennes, Service de Génétique Moléculaire et Génomique, Rennes, France
| | - Emmanuel Gyan
- CNRS EMR 7001 LNOx "Leukemic niche & redox metabolism", Tours, France.,EA 7501 GICC, université de Tours, Tours, France.,CHU de Tours, Service d'Hématologie et Thérapie Cellulaire, Tours, France
| | - François Delhommeau
- Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hôpital Saint-Antoine, Service d'Hématologie Biologique, Paris, France.,CNRS GDR 3697 Micronit "Microenvironment of tumor niches", Tours, France.,OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France
| | - Jorge Domenech
- CNRS EMR 7001 LNOx "Leukemic niche & redox metabolism", Tours, France.,EA 7501 GICC, université de Tours, Tours, France.,CHU de Tours, Service d'Hématologie Biologique, Tours, France
| | - Olivier Herault
- CNRS EMR 7001 LNOx "Leukemic niche & redox metabolism", Tours, France. .,EA 7501 GICC, université de Tours, Tours, France. .,CHU de Tours, Service d'Hématologie Biologique, Tours, France. .,FHU GOAL, Angers, France. .,Cancéropôle Grand Ouest, Nantes, France. .,CNRS GDR 3697 Micronit "Microenvironment of tumor niches", Tours, France. .,OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.
| |
Collapse
|
9
|
Mancini SJC, Balabanian K, Corre I, Gavard J, Lazennec G, Le Bousse-Kerdilès MC, Louache F, Maguer-Satta V, Mazure NM, Mechta-Grigoriou F, Peyron JF, Trichet V, Herault O. Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies. Front Immunol 2021; 12:766275. [PMID: 34858421 PMCID: PMC8631445 DOI: 10.3389/fimmu.2021.766275] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2021] [Accepted: 10/25/2021] [Indexed: 12/12/2022] Open
Abstract
Knowledge about the hematopoietic niche has evolved considerably in recent years, in particular through in vitro analyzes, mouse models and the use of xenografts. Its complexity in the human bone marrow, in particular in a context of hematological malignancy, is more difficult to decipher by these strategies and could benefit from the knowledge acquired on the niches of solid tumors. Indeed, some common features can be suspected, since the bone marrow is a frequent site of solid tumor metastases. Recent research on solid tumors has provided very interesting information on the interactions between tumoral cells and their microenvironment, composed notably of mesenchymal, endothelial and immune cells. This review thus focuses on recent discoveries on tumor niches that could help in understanding hematopoietic niches, with special attention to 4 particular points: i) the heterogeneity of carcinoma/cancer-associated fibroblasts (CAFs) and mesenchymal stem/stromal cells (MSCs), ii) niche cytokines and chemokines, iii) the energy/oxidative metabolism and communication, especially mitochondrial transfer, and iv) the vascular niche through angiogenesis and endothelial plasticity. This review highlights actors and/or pathways of the microenvironment broadly involved in cancer processes. This opens avenues for innovative therapeutic opportunities targeting not only cancer stem cells but also their regulatory tumor niche(s), in order to improve current antitumor therapies.
Collapse
Affiliation(s)
- Stéphane J C Mancini
- Centre National de la Recherche scientifique (CNRS) GDR3697, Micronit "Microenvironment of Tumor Niches", Tours, France.,INSERM UMR1236, Rennes 1 University, Etablissement Français du Sang Bretagne, Rennes, France.,Cancéropole Grand-Ouest, NET network "Niches and Epigenetics of Tumors", Nantes, France
| | - Karl Balabanian
- Centre National de la Recherche scientifique (CNRS) GDR3697, Micronit "Microenvironment of Tumor Niches", Tours, France.,Saint-Louis Research Institute, University of Paris, EMiLy, INSERM U1160, Paris, France.,The Organization for Partnerships in Leukemia (OPALE) Carnot Institute, The Organization for Partnerships in Leukemia, Paris, France
| | - Isabelle Corre
- Centre National de la Recherche scientifique (CNRS) GDR3697, Micronit "Microenvironment of Tumor Niches", Tours, France.,Cancéropole Grand-Ouest, NET network "Niches and Epigenetics of Tumors", Nantes, France.,Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), Signaling in Oncogenesis Angiogenesis and Permeability (SOAP), INSERM UMR1232, Centre National de la Recherche scientifique (CNRS) ERL600, Université de Nantes, Nantes, France
| | - Julie Gavard
- Centre National de la Recherche scientifique (CNRS) GDR3697, Micronit "Microenvironment of Tumor Niches", Tours, France.,Cancéropole Grand-Ouest, NET network "Niches and Epigenetics of Tumors", Nantes, France.,Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), Signaling in Oncogenesis Angiogenesis and Permeability (SOAP), INSERM UMR1232, Centre National de la Recherche scientifique (CNRS) ERL600, Université de Nantes, Nantes, France.,Integrated Center for Oncology, St. Herblain, France
| | - Gwendal Lazennec
- Centre National de la Recherche scientifique (CNRS) GDR3697, Micronit "Microenvironment of Tumor Niches", Tours, France.,Centre National de la Recherche scientifique (CNRS) UMR9005, SYS2DIAG-ALCEDIAG, Montpellier, France
| | - Marie-Caroline Le Bousse-Kerdilès
- Centre National de la Recherche scientifique (CNRS) GDR3697, Micronit "Microenvironment of Tumor Niches", Tours, France.,INSERM UMRS-MD1197, Paris-Saclay University, Paul-Brousse Hospital, Villejuif, France
| | - Fawzia Louache
- Centre National de la Recherche scientifique (CNRS) GDR3697, Micronit "Microenvironment of Tumor Niches", Tours, France.,INSERM UMRS-MD1197, Paris-Saclay University, Paul-Brousse Hospital, Villejuif, France
| | - Véronique Maguer-Satta
- Centre National de la Recherche scientifique (CNRS) GDR3697, Micronit "Microenvironment of Tumor Niches", Tours, France.,Cancer Research Center of Lyon (CRCL), CNRS UMR5286, INSERM U1052, Lyon 1 university, Lean Bérard Center, Lyon, France
| | - Nathalie M Mazure
- Centre National de la Recherche scientifique (CNRS) GDR3697, Micronit "Microenvironment of Tumor Niches", Tours, France.,INSERM U1065, C3M, University of Côte d'Azur (UCA), Nice, France
| | - Fatima Mechta-Grigoriou
- Centre National de la Recherche scientifique (CNRS) GDR3697, Micronit "Microenvironment of Tumor Niches", Tours, France.,Stress and Cancer Laboratory, Institut Curie, INSERM U830, Paris Sciences et Lettres (PSL) Research University, Team Babelized Ligue Nationale Contre le Cancer (LNCC), Paris, France
| | - Jean-François Peyron
- Centre National de la Recherche scientifique (CNRS) GDR3697, Micronit "Microenvironment of Tumor Niches", Tours, France.,INSERM U1065, C3M, University of Côte d'Azur (UCA), Nice, France
| | - Valérie Trichet
- Centre National de la Recherche scientifique (CNRS) GDR3697, Micronit "Microenvironment of Tumor Niches", Tours, France.,Cancéropole Grand-Ouest, NET network "Niches and Epigenetics of Tumors", Nantes, France.,INSERM UMR1238 Phy-Os, Université de Nantes, Nantes, France
| | - Olivier Herault
- Centre National de la Recherche scientifique (CNRS) GDR3697, Micronit "Microenvironment of Tumor Niches", Tours, France.,Cancéropole Grand-Ouest, NET network "Niches and Epigenetics of Tumors", Nantes, France.,The Organization for Partnerships in Leukemia (OPALE) Carnot Institute, The Organization for Partnerships in Leukemia, Paris, France.,Centre National de la Recherche scientifique (CNRS) ERL7001 LNOx, EA7501, Tours University, Tours, France.,Department of Biological Hematology, Tours University Hospital, Tours, France
| |
Collapse
|
10
|
Vignon C, Lachot S, Foucault A, Ravalet N, Gyan E, Picou F, Herault B, Le Nail L, Bene MC, Herault O. Reactive oxygen species levels differentiate
CD34
+
human progenitors based on
CD38
expression. Cytometry 2020; 98:516-521. [DOI: 10.1002/cyto.b.21948] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/01/2019] [Revised: 07/01/2020] [Accepted: 07/30/2020] [Indexed: 12/18/2022]
Affiliation(s)
- Christine Vignon
- CNRS ERL7001 LNOx “Leukemic Niche & redox metabolism” and EA7501 GICC Tours University Tours France
| | - Sébastien Lachot
- Tours University Hospital Department of Biological Hematology Tours France
| | - Amélie Foucault
- CNRS ERL7001 LNOx “Leukemic Niche & redox metabolism” and EA7501 GICC Tours University Tours France
- Tours University Hospital Department of Biological Hematology Tours France
| | - Noémie Ravalet
- CNRS ERL7001 LNOx “Leukemic Niche & redox metabolism” and EA7501 GICC Tours University Tours France
- Tours University Hospital Department of Biological Hematology Tours France
| | - Emmanuel Gyan
- CNRS ERL7001 LNOx “Leukemic Niche & redox metabolism” and EA7501 GICC Tours University Tours France
- Tours University Hospital Department of Hematology and Cell Therapy Tours France
| | - Frédéric Picou
- CNRS ERL7001 LNOx “Leukemic Niche & redox metabolism” and EA7501 GICC Tours University Tours France
- Tours University Hospital Department of Biological Hematology Tours France
| | - Beatrice Herault
- French Blood Establishment (EFS) Centre‐Pays de la Loire Tours France
| | | | - Marie C. Bene
- Nantes University Hospital Hematology Biology & CIRCNA Nantes France
| | - Olivier Herault
- CNRS ERL7001 LNOx “Leukemic Niche & redox metabolism” and EA7501 GICC Tours University Tours France
- Tours University Hospital Department of Biological Hematology Tours France
| |
Collapse
|
11
|
Hirsch P, Ravalet N, Guermouche H, Gallay N, Gyan E, Delhommeau F, Herault O. Clonal hematopoiesis in the bone marrow and blood of healthy volunteers. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.7517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7517 Background: Clonal hematopoiesis of indeterminate potential (CHIP) has been described in blood samples from large series of patients. Its prevalence and consequences remain questioned because sequencing methods vary and because most studies were performed in cohorts of individuals suffering from non-hematological diseases (solid cancers, diabetes, cardiovascular or psychiatric diseases). CHIP has been described as a risk factor for blood cancer. However, the diagnosis of most blood cancers relies on morphologic and genetic examination of the bone marrow, and clonal hematopoiesis has never been evaluated in bone marrow samples from healthy individuals. Hence, it is not clear whether the current definition of CHIP is clinically relevant. To address this issue, we studied clonal hematopoiesis in paired peripheral blood and bone marrow samples from an unprecedented cohort of rigorously selected healthy volunteers. Methods: Here, we investigated the frequency of clonal hematopoiesis in 82 paired bone marrow and blood samples from carefully selected healthy adult volunteers (HEALTHOX clinical trial, ClinicalTrials.gov Identifier: NCT02789839). This study was approved by the ethics committees (CPP Tours and AFSSAPS identifier ID-RCB: 2011-A00262-39; CPP Ile-de-France III: 2753). Forty-one genes known to be mutated in myeloid malignancies were sequenced with a 1% threshold of detection. All variants were checked using IGV software v2.3. Statistical analyses were performed using Mann-Whitney, chi-squared, Fisher’s exact, Wilcoxon matched-pairs tests or Spearman correlation using GraphPad Prism 6. Results: In bone marrow samples, clones were found in almost 40 % of healthy volunteers over 50 years-old (yo). The most frequent mutations were found in DNMT3A (48%) and TET2 (28%) and the other mutations were found in ASXL1 (8%), JAK2 (8%), RAD21 (4%) and SRSF2 (4%) with one individual carrying three variants. Blood parameters and bone marrow smears were normal with the exception of two individuals with mild macrocytosis or thrombocytosis. Clonal hematopoiesis cases differed from others by age (62.8 vs. 38.6 years, P < .0001) and platelet count (294 vs. 241 G/L, P < .0208). Conclusions: These results confirm that clonal hematopoiesis is a very common condition in healthy adults over 50 years old. Consequently, the detection of driver myeloid mutations should be interpreted with caution in the absence of cytologic abnormalities in the blood and/or in the bone marrow.
Collapse
Affiliation(s)
- Pierre Hirsch
- Sorbonne Université, UMRS 938, APHP, Hôpital Saint-Antoine, Paris, France
| | - Noémie Ravalet
- Tours University Hospital and CNRS ERL7001 LNOX, EA7501, Tours, France
| | - Helene Guermouche
- Sorbonne Université, UMRS 938, APHP, Hôpital Saint-Antoine, Paris, France
| | - Nathalie Gallay
- Tours University Hospital and CNRS ERL7001 LNOX, EA7501, Tours, France
| | - Emmanuel Gyan
- Tours University Hospital and CNRS ERL7001 LNOX, EA7501, Tours, France
| | | | - Olivier Herault
- Tours University Hospital and CNRS ERL7001 LNOX, EA7501, Tours, France
| |
Collapse
|
12
|
Vallet N, Foucault A, Picou F, Gyan E, Herault O. Meta-analysis of case-control studies to examine the relationship between occupational pesticide exposure and risk of acute myeloid leukemia. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.7540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7540 Background: Occupational pesticide exposure (OPE) is associated with the risk of developing lymphoid malignancies, but less information is available on large cohorts about the risk of occurrence of acute myeloid leukemia (AML). To answer this question, we performed a meta-analysis including relevant adult case-control studies which reported OPE. Methods: Following PRISMA and MOOSE guidelines, two investigators performed a systematic search in PubMed and Cochrane databases for case-control studies evaluating the association between OPE and AML between 1946 and August 28, 2018. In order to identify the maximum number of studies, keywords related to demographical, pesticides and chemicals data exposures were used. Studies reporting AML diagnosis based only on death certificates, controls from cancer databases and pediatric cases (<15 years-old) were not included. Statistical analyses were performed with R software and the ‘mefafor’ package. Results: Fifteen studies which included 4,068 AML patients and 250,975 control subjects were included. Using a random effects model, the overall analysis showed a significant adverse association between OPE and AML with OR=1.49 (95%CI: 1.10-2.01), and a significant heterogeneity between studies ( I² =0.73, p<0.001). The robustness was checked after sequential exclusion of one study at a time which did not influence the overall OR estimate. A publication bias underestimating the OR was suggested by an asymmetrical funnel plot. Using trim-and-fill method, hypothetical missing studies were added studies in order to adjust the OR (OR=1.76 [95%CI: 1.30-2.38]. A stratified analysis showed that the association was significant in Asian populations (OR=1.74; 95%CI: 1.32-2.30) and upon exposure to insecticides (OR=1.45; 95%CI: 1.16-1.81), yet partly influenced by other factors, since most of the studies reported unadjusted results (n=8, 53%). Data on biological characteristics were unavailable to stratify patients according to AML molecular or cytogenetic characteristics. Conclusions: From this new extensive review and analysis, it clearly appears that AML should be considered as occupational illness in patients with demonstrated OPE. Further studies will have to focus on the biological effects of individual and pesticides cocktails in order to determine the pathogenesis mechanisms involved in leukemogenesis, and to improve individual protection.
Collapse
Affiliation(s)
- Nicolas Vallet
- Tours University Hospital and ERL7001 LNOX, EA 3549, Tours, France
| | - Amélie Foucault
- Tours University Hospital and CNRS ERL7001 LNOX, EA 3549, Tours, France
| | - Frederic Picou
- Tours University Hospital and CNRS ERL7001 LNOX, EA 3549, Tours, France
| | - Emmanuel Gyan
- Tours University Hospital and CNRS ERL7001 LNOX, EA7501, Tours, France
| | - Olivier Herault
- Tours University Hospital and CNRS ERL7001 LNOX, EA7501, Tours, France
| |
Collapse
|
13
|
Kouzi F, Zibara K, Bourgeais J, Picou F, Gallay N, Brossaud J, Dakik H, Roux B, Hamard S, Le Nail LR, Hleihel R, Foucault A, Ravalet N, Rouleux-Bonnin F, Gouilleux F, Mazurier F, Bene MC, Akl H, Gyan E, Domenech J, El-Sabban M, Herault O. Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells. Oncogene 2019; 39:1198-1212. [PMID: 31649334 PMCID: PMC7002301 DOI: 10.1038/s41388-019-1069-y] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Revised: 10/07/2019] [Accepted: 10/10/2019] [Indexed: 01/09/2023]
Abstract
The bone marrow (BM) niche impacts the progression of acute myeloid leukemia (AML) by favoring the chemoresistance of AML cells. Intimate interactions between leukemic cells and BM mesenchymal stromal cells (BM-MSCs) play key roles in this process. Direct intercellular communications between hematopoietic cells and BM-MSCs involve connexins, components of gap junctions. We postulated that blocking gap junction assembly could modify cell–cell interactions in the leukemic niche and consequently the chemoresistance. The comparison of BM-MSCs from AML patients and healthy donors revealed a specific profile of connexins in BM-MSCs of the leukemic niche and the effects of carbenoxolone (CBX), a gap junction disruptor, were evaluated on AML cells. CBX presents an antileukemic effect without affecting normal BM-CD34+ progenitor cells. The proapoptotic effect of CBX on AML cells is in line with the extinction of energy metabolism. CBX acts synergistically with cytarabine (Ara-C) in vitro and in vivo. Coculture experiments of AML cells with BM-MSCs revealed that CBX neutralizes the protective effect of the niche against the Ara-C-induced apoptosis of leukemic cells. Altogether, these results suggest that CBX could be of therapeutic interest to reduce the chemoresistance favored by the leukemic niche, by targeting gap junctions, without affecting normal hematopoiesis.
Collapse
Affiliation(s)
- Farah Kouzi
- CNRS ERL7001 LNOx "Leukemic Niche & Redox Metabolism", Tours, France.,EA7501 GICC, University of Tours, Faculty of Medicine, Tours, France.,PRASE, DSST, Lebanese University, Beirut, Lebanon
| | - Kazem Zibara
- PRASE, DSST, Lebanese University, Beirut, Lebanon.,Biology Department, Faculty of Sciences, Lebanese University, Beirut, Lebanon
| | - Jerome Bourgeais
- CNRS ERL7001 LNOx "Leukemic Niche & Redox Metabolism", Tours, France.,EA7501 GICC, University of Tours, Faculty of Medicine, Tours, France.,Department of Biological Hematology, Tours University Hospital, Tours, France
| | - Frederic Picou
- CNRS ERL7001 LNOx "Leukemic Niche & Redox Metabolism", Tours, France.,EA7501 GICC, University of Tours, Faculty of Medicine, Tours, France.,Department of Biological Hematology, Tours University Hospital, Tours, France
| | - Nathalie Gallay
- CNRS ERL7001 LNOx "Leukemic Niche & Redox Metabolism", Tours, France.,EA7501 GICC, University of Tours, Faculty of Medicine, Tours, France.,Department of Biological Hematology, Tours University Hospital, Tours, France
| | - Julie Brossaud
- Department of Nuclear Medicine, Bordeaux University Hospital, Pessac, France
| | - Hassan Dakik
- CNRS ERL7001 LNOx "Leukemic Niche & Redox Metabolism", Tours, France.,EA7501 GICC, University of Tours, Faculty of Medicine, Tours, France
| | - Benjamin Roux
- CNRS ERL7001 LNOx "Leukemic Niche & Redox Metabolism", Tours, France.,EA7501 GICC, University of Tours, Faculty of Medicine, Tours, France.,Department of Biological Hematology, Tours University Hospital, Tours, France
| | - Sophie Hamard
- CNRS ERL7001 LNOx "Leukemic Niche & Redox Metabolism", Tours, France.,EA7501 GICC, University of Tours, Faculty of Medicine, Tours, France
| | | | - Rita Hleihel
- Department of Anatomy, Cell Biology, and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.,Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
| | - Amelie Foucault
- CNRS ERL7001 LNOx "Leukemic Niche & Redox Metabolism", Tours, France.,EA7501 GICC, University of Tours, Faculty of Medicine, Tours, France.,Department of Biological Hematology, Tours University Hospital, Tours, France
| | - Noemie Ravalet
- CNRS ERL7001 LNOx "Leukemic Niche & Redox Metabolism", Tours, France.,EA7501 GICC, University of Tours, Faculty of Medicine, Tours, France.,Department of Biological Hematology, Tours University Hospital, Tours, France
| | - Florence Rouleux-Bonnin
- CNRS ERL7001 LNOx "Leukemic Niche & Redox Metabolism", Tours, France.,EA7501 GICC, University of Tours, Faculty of Medicine, Tours, France
| | - Fabrice Gouilleux
- CNRS ERL7001 LNOx "Leukemic Niche & Redox Metabolism", Tours, France.,EA7501 GICC, University of Tours, Faculty of Medicine, Tours, France
| | - Frederic Mazurier
- CNRS ERL7001 LNOx "Leukemic Niche & Redox Metabolism", Tours, France.,EA7501 GICC, University of Tours, Faculty of Medicine, Tours, France
| | - Marie C Bene
- Department of Biological Hematology, Nantes University Hospital, CRCINA, Nantes, France
| | - Haidar Akl
- PRASE, DSST, Lebanese University, Beirut, Lebanon.,Biology Department, Faculty of Sciences, Lebanese University, Beirut, Lebanon
| | - Emmanuel Gyan
- CNRS ERL7001 LNOx "Leukemic Niche & Redox Metabolism", Tours, France.,EA7501 GICC, University of Tours, Faculty of Medicine, Tours, France.,Department of Hematology and Cell Therapy, Tours University Hospital, Tours, France
| | - Jorge Domenech
- CNRS ERL7001 LNOx "Leukemic Niche & Redox Metabolism", Tours, France.,EA7501 GICC, University of Tours, Faculty of Medicine, Tours, France.,Department of Biological Hematology, Tours University Hospital, Tours, France
| | - Marwan El-Sabban
- Department of Anatomy, Cell Biology, and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
| | - Olivier Herault
- CNRS ERL7001 LNOx "Leukemic Niche & Redox Metabolism", Tours, France. .,EA7501 GICC, University of Tours, Faculty of Medicine, Tours, France. .,Department of Biological Hematology, Tours University Hospital, Tours, France.
| |
Collapse
|
14
|
Leveque X, Hochane M, Geraldo F, Dumont S, Gratas C, Oliver L, Gaignier C, Trichet V, Layrolle P, Heymann D, Herault O, Vallette FM, Olivier C. Low-Dose Pesticide Mixture Induces Accelerated Mesenchymal Stem Cell Aging In Vitro. Stem Cells 2019; 37:1083-1094. [PMID: 30977188 PMCID: PMC6850038 DOI: 10.1002/stem.3014] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2018] [Accepted: 02/11/2019] [Indexed: 12/24/2022]
Abstract
The general population is chronically exposed to multiple environmental contaminants such as pesticides. We have previously demonstrated that human mesenchymal stem cells (MSCs) exposed in vitro to low doses of a mixture of seven common pesticides showed a permanent phenotype modification with a specific induction of an oxidative stress-related senescence. Pesticide mixture also induced a shift in MSC differentiation toward adipogenesis. Thus, we hypothesized that common combination of pesticides may induce a premature cellular aging of adult MSCs. Our goal was to evaluate if the prolonged exposure to pesticide mixture could accelerate aging-related markers and in particular deteriorate the immunosuppressive properties of MSCs. MSCs exposed to pesticide mixture, under long-term culture and obtained from aging donor, were compared by bulk RNA sequencing analysis. Aging, senescence, and immunomodulatory markers were compared. The protein expression of cellular aging-associated metabolic markers and immune function of MSCs were analyzed. Functional analysis of the secretome impacts on immunomodulatory properties of MSCs was realized after 21 days' exposure to pesticide mixture. The RNA sequencing analysis of MSCs exposed to pesticide showed some similarities with cells from prolonged culture, but also with the MSCs of an aged donor. Changes in the metabolic markers MDH1, GOT and SIRT3, as well as an alteration in the modulation of active T cells and modifications in cytokine production are all associated with cellular aging. A modified functional profile was found with similarities to aging process. Stem Cells 2019;37:1083-1094.
Collapse
Affiliation(s)
| | | | - Fanny Geraldo
- CRCINAINSERM U1232, Université de NantesNantesFrance
| | - Solene Dumont
- CRCINAINSERM U1232, Université de NantesNantesFrance
| | - Catherine Gratas
- CRCINAINSERM U1232, Université de NantesNantesFrance
- LabEx Immunotherapy, Graft, OncologyNantesFrance
- CHU de NantesNantesFrance
| | - Lisa Oliver
- CRCINAINSERM U1232, Université de NantesNantesFrance
- LabEx Immunotherapy, Graft, OncologyNantesFrance
- CHU de NantesNantesFrance
| | - Claire Gaignier
- CRCINAINSERM U1232, Université de NantesNantesFrance
- Université de Nantes, UFR Sciences Biologiques et PharmaceutiquesNantesFrance
| | - Valérie Trichet
- UMR1238 INSERM, Université de Nantes, PHY‐OS, “Bone Sarcomas and Remodeling of Calcified Tissues,” Medical SchoolNantesFrance
| | - Pierre Layrolle
- UMR1238 INSERM, Université de Nantes, PHY‐OS, “Bone Sarcomas and Remodeling of Calcified Tissues,” Medical SchoolNantesFrance
| | - Dominique Heymann
- CRCINAINSERM U1232, Université de NantesNantesFrance
- LaBCTInstitut de Cancérologie de l'OuestSt. Herblain CedexFrance
| | - Olivier Herault
- Centre Hospitalier Régional Universitaire de ToursService d'Hématologie BiologiqueCedex 9 ToursFrance
- National Center for Scientific Research ERL 7001 LNOxUniversité de ToursToursFrance
- National Center for Scientific Research GDR 3697ParisFrance
| | - François M. Vallette
- CRCINAINSERM U1232, Université de NantesNantesFrance
- LabEx Immunotherapy, Graft, OncologyNantesFrance
- LaBCTInstitut de Cancérologie de l'OuestSt. Herblain CedexFrance
- National Center for Scientific Research GDR 3697ParisFrance
| | - Christophe Olivier
- CRCINAINSERM U1232, Université de NantesNantesFrance
- Université de Nantes, UFR Sciences Biologiques et PharmaceutiquesNantesFrance
- National Center for Scientific Research GDR 3697ParisFrance
| |
Collapse
|
15
|
Ravalet N, Picou F, Gombert M, Foucault A, Renoult E, Gyan E, Lachot S, Rault E, Herault O. New strategy of early detection of myelodysplastic syndromes on the complete blood count with Unicel DxH 800 Coulter® analyzer. Clin Chim Acta 2019. [DOI: 10.1016/j.cca.2019.03.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
16
|
Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, Karim Z, Puy H, Alary AS, Ducamp S, Verdier F, Bouilloux C, Rousseau A, Jacob MC, Debliquis A, Charpentier A, Gyan E, Anglaret B, Leyronnas C, Corm S, Slama B, Cheze S, Laribi K, Amé S, Rose C, Lachenal F, Toma A, Pica GM, Carre M, Garban F, Mariette C, Cahn JY, Meunier M, Herault O, Fenaux P, Wagner-Ballon O, Bardet V, Dreyfus F, Fontenay M. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. Haematologica 2018; 104:497-504. [PMID: 30287621 PMCID: PMC6395339 DOI: 10.3324/haematol.2018.203158] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2018] [Accepted: 10/02/2018] [Indexed: 12/29/2022] Open
Abstract
Erythropoiesis-stimulating agents are generally the first line of treatment of anemia in patients with lower-risk myelodysplastic syndrome. We prospectively investigated the predictive value of somatic mutations, and biomarkers of ineffective erythropoiesis including the flow cytometry RED score, serum growth-differentiation factor-15, and hepcidin levels. Inclusion criteria were no prior treatment with erythropoiesis-stimulating agents, low- or intermediate-1-risk myelodysplastic syndrome according to the International Prognostic Scoring System, and a hemoglobin level <10 g/dL. Patients could be red blood cell transfusion-dependent or not and were given epoetin zeta 40 000 IU/week. Serum erythropoietin level, iron parameters, hepcidin, flow cytometry Ogata and RED scores, and growth-differentiation factor-15 levels were determined at baseline, and molecular analysis by next-generation sequencing was also conducted. Erythroid response (defined according to the International Working Group 2006 criteria) was assessed at week 12. Seventy patients, with a median age of 78 years, were included in the study. There were 22 patients with refractory cytopenia with multilineage dysplasia, 19 with refractory cytopenia with unilineage dysplasia, 14 with refractory anemia with ring sideroblasts, four with refractory anemia with excess blasts-1, six with chronic myelomonocytic leukemia, two with del5q-and three with unclassifiable myelodysplastic syndrome. According to the revised International Prognostic Scoring System, 13 had very low risk, 47 had low risk, nine intermediate risk and one had high-risk disease. Twenty patients were transfusion dependent. Forty-eight percent had an erythroid response and the median duration of the response was 26 months. At baseline, non-responders had significantly higher RED scores and lower hepcidin:ferritin ratios. In multivariate analysis, only a RED score >4 (P=0.05) and a hepcidin:ferritin ratio <9 (P=0.02) were statistically significantly associated with worse erythroid response. The median response duration was shorter in patients with growth-differentiation factor-15 >2000 pg/mL and a hepcidin:ferritin ratio <9 (P=0.0008 and P=0.01, respectively). In multivariate analysis, both variables were associated with shorter response duration. Erythroid response to epoetin zeta was similar to that obtained with other erythropoiesis-stimulating agents and was correlated with higher baseline hepcidin:ferritin ratio and lower RED score. ClinicalTrials.gov registration: NCT 03598582.
Collapse
Affiliation(s)
- Sophie Park
- Department of Hematology, CHU Grenoble-Alpes, Grenoble .,Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Grenoble
| | - Olivier Kosmider
- Assistance Publique-Hôpitaux de Paris (AP-HP), Service d'Hématologie Biologique, Hôpitaux Universitaires Paris Centre, Institut Cochin, Université Paris Descartes
| | | | - Bernard Drenou
- Department of Hematology, Hôpital Emile Muller, CH de Mulhouse
| | - Nicolas Chapuis
- INSERM UMR1149, CNRS 8252 - Centre de Recherche sur l'Inflammation (CRI) Equipe "Hème, Fer et Pathologies Inflammatoires", Labex GREX, Centre Français des Porphyries - Hôpital Louis Mourier HUPNVS, Paris
| | - Thibaud Lefebvre
- Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris Descartes University
| | - Zoubida Karim
- INSERM UMR1149, CNRS 8252 - Centre de Recherche sur l'Inflammation (CRI) Equipe "Hème, Fer et Pathologies Inflammatoires", Labex GREX, Centre Français des Porphyries - Hôpital Louis Mourier HUPNVS, Paris
| | - Hervé Puy
- INSERM UMR1149, CNRS 8252 - Centre de Recherche sur l'Inflammation (CRI) Equipe "Hème, Fer et Pathologies Inflammatoires", Labex GREX, Centre Français des Porphyries - Hôpital Louis Mourier HUPNVS, Paris
| | - Anne Sophie Alary
- Assistance Publique-Hôpitaux de Paris (AP-HP), Service d'Hématologie Biologique, Hôpitaux Universitaires Paris Centre, Institut Cochin, Université Paris Descartes
| | - Sarah Ducamp
- Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris Descartes University
| | - Frédérique Verdier
- Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris Descartes University
| | - Cécile Bouilloux
- Department of Hematology, CHU Grenoble-Alpes, Grenoble.,Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Grenoble
| | - Alice Rousseau
- Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris Descartes University
| | | | | | | | | | | | | | | | | | | | | | - Shanti Amé
- Department of Hematology, Hôpital Civil, CHU Strasbourg
| | - Christian Rose
- Department of Hematology, Hôpital Saint Vincent de Paul, Lille
| | | | - Andrea Toma
- Department of Hematology, Hôpital Universitaire Henri Mondor, AP-HP, Université Paris 12, Créteil
| | | | - Martin Carre
- Department of Hematology, CHU Grenoble-Alpes, Grenoble.,Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Grenoble
| | - Frédéric Garban
- Department of Hematology, CHU Grenoble-Alpes, Grenoble.,Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Grenoble
| | - Clara Mariette
- Department of Hematology, CHU Grenoble-Alpes, Grenoble.,Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Grenoble
| | - Jean-Yves Cahn
- Department of Hematology, CHU Grenoble-Alpes, Grenoble.,Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Grenoble
| | - Mathieu Meunier
- Department of Hematology, CHU Grenoble-Alpes, Grenoble.,Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Grenoble
| | | | - Pierre Fenaux
- Department of Hematology, Saint Louis Hospital, AP-HP, Université Paris Diderot
| | - Orianne Wagner-Ballon
- Département d'Hématologie et Immunologie Biologiques, Hôpital Universitaire Henri Mondor, Creteil
| | - Valerie Bardet
- Service d'Hématologie Immunologie Transfusion, Hôpitaux Universitaires Paris Ile de France-Ouest, AP-HP
| | | | - Michaela Fontenay
- Assistance Publique-Hôpitaux de Paris (AP-HP), Service d'Hématologie Biologique, Hôpitaux Universitaires Paris Centre, Institut Cochin, Université Paris Descartes
| |
Collapse
|
17
|
Girerd S, Tosca L, Herault O, Vignon C, Biard D, Aggoune D, Dkhissi F, Bonnet ML, Sorel N, Desterke C, Bennaceur-Griscelli A, Tachdjian G, Guilhot F, Guilhot J, Chomel JC, Turhan AG. Superoxide dismutase 2 (SOD2) contributes to genetic stability of native and T315I-mutated BCR-ABL expressing leukemic cells. Biochem Biophys Res Commun 2018; 498:715-722. [DOI: 10.1016/j.bbrc.2018.03.023] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2018] [Accepted: 03/05/2018] [Indexed: 01/12/2023]
|
18
|
Chalopin T, Barillot I, Biny JP, Arbion F, Besson M, Santiago-Ribeiro M, Piver E, Herault O, Gyan E, Benboubker L. Primary solitary plasmacytoma of the liver - successful treatment with fractionated stereotactic radiotherapy (Cyberknife®): a case report. J Med Case Rep 2017; 11:193. [PMID: 28716071 PMCID: PMC5514462 DOI: 10.1186/s13256-017-1358-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Accepted: 06/19/2017] [Indexed: 11/29/2022] Open
Abstract
Background Solitary plasmacytoma of the liver is a very rare and aggressive form of plasma cell dyscrasia. To the best of our knowledge, very few cases have been reported without systemic disease. We reported a rare case of hepatic solitary plasmacytoma that successfully responded to fractionated stereotactic radiotherapy. Case presentation A 64-year-old white French man had monoclonal gammopathy of the immune globulin G lambda type; he developed a cholestasis and cytolysis with the discovery of a subscapular nodule. A biopsy showed plasma cells and, for several reasons, the decision was made to use the fractionated stereotactic radiotherapy strategy. After 20 months, he is asymptomatic and the immune globulin G component has completely disappeared. Conclusion We suggest considering Cyberknife® radiosurgery as an option for the treatment of hepatic solitary plasmacytoma.
Collapse
Affiliation(s)
- Thomas Chalopin
- Department of Hematology, University Hospital of Tours, Tours, France. .,Centre Hospitalier Universitaire de Tours, Hôpital Bretonneau, 2 boulevard Tonnellé, 37044, Tours cedex 9, France.
| | - Isabelle Barillot
- Department of Radiation Oncology (CORAD), University Hospital of Tours, Tours, France
| | - Jean-Paul Biny
- Anatomopathology Center of Origet, Saint-Cyr sur Loire, France
| | - Flavie Arbion
- Department of Anatomopathology, University Hospital of Tours, Tours, France
| | - Marie Besson
- Department of Medical Imaging, University Hospital of Tours, Tours, France
| | | | - Eric Piver
- Department of Biochemistry, University Hospital of Tours, Tours, France
| | - Olivier Herault
- Department of Biologic Hematology, University of Tours, Tours, France
| | - Emmanuel Gyan
- Department of Hematology, University Hospital of Tours, Tours, France
| | - Lotfi Benboubker
- Department of Hematology, University Hospital of Tours, Tours, France
| |
Collapse
|
19
|
Maillot F, Veyrat-Durebex C, Debeissat C, Blasco H, Patin F, Henique H, Emond P, Antar C, Herault O. Diminution de l’expression des gènes antioxydants dans les leucocytes des patients adultes atteints de phénylcétonurie. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.03.331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
20
|
Poulain L, Sujobert P, Zylbersztejn F, Barreau S, Stuani L, Lambert M, Palama TL, Chesnais V, Birsen R, Vergez F, Farge T, Chenevier-Gobeaux C, Fraisse M, Bouillaud F, Debeissat C, Herault O, Récher C, Lacombe C, Fontenay M, Mayeux P, Maciel TT, Portais JC, Sarry JE, Tamburini J, Bouscary D, Chapuis N. High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells. Leukemia 2017; 31:2326-2335. [PMID: 28280275 DOI: 10.1038/leu.2017.81] [Citation(s) in RCA: 92] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Revised: 02/13/2017] [Accepted: 02/27/2017] [Indexed: 01/03/2023]
Abstract
Alterations in metabolic activities are cancer hallmarks that offer a wide range of new therapeutic opportunities. Here we decipher the interplay between mTORC1 activity and glucose metabolism in acute myeloid leukemia (AML). We show that mTORC1 signaling that is constantly overactivated in AML cells promotes glycolysis and leads to glucose addiction. The level of mTORC1 activity determines the sensitivity of AML cells to glycolysis inhibition as switch-off mTORC1 activity leads to glucose-independent cell survival that is sustained by an increase in mitochondrial oxidative phosphorylation. Metabolic analysis identified the pentose phosphate pathway (PPP) as an important pro-survival pathway for glucose metabolism in AML cells with high mTORC1 activity and provided a clear rational for targeting glucose-6-phosphate dehydrogenase (G6PD) in AML. Indeed, our analysis of the cancer genome atlas AML database pinpointed G6PD as a new biomarker in AML, as its overexpression correlated with an adverse prognosis in this cohort. Targeting the PPP using the G6PD inhibitor 6-aminonicotinamide induces in vitro and in vivo cytotoxicity against AML cells and synergistically sensitizes leukemic cells to chemotherapy. Our results demonstrate that high mTORC1 activity creates a specific vulnerability to G6PD inhibition that may work as a new AML therapy.
Collapse
Affiliation(s)
- L Poulain
- INSERM U1016, Institut Cochin, Paris, France.,CNRS UMR8104, Paris, France.,Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
| | - P Sujobert
- INSERM U1016, Institut Cochin, Paris, France.,CNRS UMR8104, Paris, France.,Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
| | - F Zylbersztejn
- INSERM UMR1163, Laboratory of Cellular and Molecular Mechanisms of Haematological Disorders and Therapeutic Implications, Paris, France.,Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Paris, France
| | - S Barreau
- INSERM U1016, Institut Cochin, Paris, France.,CNRS UMR8104, Paris, France.,Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
| | - L Stuani
- INSERM, UMR1037, Cancer Research Center of Toulouse, Toulouse, France.,Université de Toulouse III Paul Sabatier, INSA, UPS, INP, LISBP, Toulouse, France
| | - M Lambert
- INSERM U1016, Institut Cochin, Paris, France.,CNRS UMR8104, Paris, France.,Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
| | - T L Palama
- Université de Toulouse III Paul Sabatier, INSA, UPS, INP, LISBP, Toulouse, France.,LISBP, Université de Toulouse, CNRS, INRA, INSA, Toulouse, France
| | - V Chesnais
- INSERM U1016, Institut Cochin, Paris, France.,CNRS UMR8104, Paris, France.,Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
| | - R Birsen
- INSERM U1016, Institut Cochin, Paris, France.,CNRS UMR8104, Paris, France.,Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
| | - F Vergez
- INSERM, UMR1037, Cancer Research Center of Toulouse, Toulouse, France.,Université de Toulouse III Paul Sabatier, INSA, UPS, INP, LISBP, Toulouse, France
| | - T Farge
- INSERM, UMR1037, Cancer Research Center of Toulouse, Toulouse, France.,Université de Toulouse III Paul Sabatier, INSA, UPS, INP, LISBP, Toulouse, France
| | - C Chenevier-Gobeaux
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service de Diagnostic Biologique Automatisé, Paris, France
| | - M Fraisse
- INSERM, UMR1037, Cancer Research Center of Toulouse, Toulouse, France.,Université de Toulouse III Paul Sabatier, INSA, UPS, INP, LISBP, Toulouse, France
| | - F Bouillaud
- INSERM U1016, Institut Cochin, Paris, France.,CNRS UMR8104, Paris, France.,Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France
| | | | | | - C Récher
- INSERM, UMR1037, Cancer Research Center of Toulouse, Toulouse, France.,Université de Toulouse III Paul Sabatier, INSA, UPS, INP, LISBP, Toulouse, France
| | - C Lacombe
- INSERM U1016, Institut Cochin, Paris, France.,CNRS UMR8104, Paris, France.,Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
| | - M Fontenay
- INSERM U1016, Institut Cochin, Paris, France.,CNRS UMR8104, Paris, France.,Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France.,Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie biologique, F-75014 Paris, France
| | - P Mayeux
- INSERM U1016, Institut Cochin, Paris, France.,CNRS UMR8104, Paris, France.,Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
| | - T T Maciel
- INSERM UMR1163, Laboratory of Cellular and Molecular Mechanisms of Haematological Disorders and Therapeutic Implications, Paris, France.,Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Paris, France
| | - J-C Portais
- Université de Toulouse III Paul Sabatier, INSA, UPS, INP, LISBP, Toulouse, France.,LISBP, Université de Toulouse, CNRS, INRA, INSA, Toulouse, France
| | - J-E Sarry
- INSERM, UMR1037, Cancer Research Center of Toulouse, Toulouse, France.,Université de Toulouse III Paul Sabatier, INSA, UPS, INP, LISBP, Toulouse, France
| | - J Tamburini
- INSERM U1016, Institut Cochin, Paris, France.,CNRS UMR8104, Paris, France.,Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France.,Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie clinique, F-75014 Paris, France
| | - D Bouscary
- INSERM U1016, Institut Cochin, Paris, France.,CNRS UMR8104, Paris, France.,Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France.,Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie clinique, F-75014 Paris, France
| | - N Chapuis
- INSERM U1016, Institut Cochin, Paris, France.,CNRS UMR8104, Paris, France.,Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France.,Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie clinique, F-75014 Paris, France
| |
Collapse
|
21
|
Zhang Y, Dépond M, He L, Foudi A, Kwarteng EO, Lauret E, Plo I, Desterke C, Dessen P, Fujii N, Opolon P, Herault O, Solary E, Vainchenker W, Joulin V, Louache F, Wittner M. CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress. Sci Rep 2016; 6:37827. [PMID: 27886253 PMCID: PMC5122894 DOI: 10.1038/srep37827] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2016] [Accepted: 11/02/2016] [Indexed: 01/17/2023] Open
Abstract
Hematopoietic stem cells (HSCs) undergo self-renewal to maintain hematopoietic homeostasis for lifetime, which is regulated by the bone marrow (BM) microenvironment. The chemokine receptor CXCR4 and its ligand CXCL12 are critical factors supporting quiescence and BM retention of HSCs. Here, we report an unknown function of CXCR4/CXCL12 axis in the protection of HSCs against oxidative stress. Disruption of CXCR4 receptor in mice leads to increased endogenous production of reactive oxygen species (ROS), resulting in p38 MAPK activation, increased DNA double-strand breaks and apoptosis leading to marked reduction in HSC repopulating potential. Increased ROS levels are directly responsible for exhaustion of the HSC pool and are not linked to loss of quiescence of CXCR4-deficient HSCs. Furthermore, we report that CXCL12 has a direct rescue effect on oxidative stress-induced HSC damage at the mitochondrial level. These data highlight the importance of CXCR4/CXCL12 axis in the regulation of lifespan of HSCs by limiting ROS generation and genotoxic stress.
Collapse
Affiliation(s)
- Yanyan Zhang
- Paris-Saclay University, UMRS-1170, Gustave Roussy, Villejuif, France
| | - Mallorie Dépond
- Paris-Saclay University, UMRS-1170, Gustave Roussy, Villejuif, France
| | - Liang He
- Paris-Saclay University, UMRS-1170, Gustave Roussy, Villejuif, France
| | - Adlen Foudi
- Paris-Saclay University, INSERM U935, Andre Lwoff Institute, Paul Brousse Hospital, Villejuif, France
| | | | - Evelyne Lauret
- Paris Descartes University, CNRS (UMR 8104), Inserm U1016, Institut Cochin, Paris, France
| | - Isabelle Plo
- Paris-Saclay University, UMRS-1170, Gustave Roussy, Villejuif, France
| | - Christophe Desterke
- Paris-Saclay University, UFR Medicine, INSERM UMS 33, Andre Lwoff Institute, Paul Brousse Hospital, Villejuif, France
| | - Philippe Dessen
- Bioinformatic platform, UMS AMMICA, INSERM US23/CNRS UMS3665, Gustave Roussy, Villejuif, France
| | - Nobutaka Fujii
- Kyoto University, Graduate School of Pharmaceutical Sciences, Kyoto, Japan
| | - Paule Opolon
- Laboratoire de pathologie expérimentale, Gustave Roussy, Villejuif, France
| | - Olivier Herault
- CNRS UMR 7292 GICC, Tours, France.,CNRS GDR 3697 MicroNiT, France
| | - Eric Solary
- Paris-Saclay University, UMRS-1170, Gustave Roussy, Villejuif, France
| | | | - Virginie Joulin
- Paris-Saclay University, UMRS-1170, Gustave Roussy, Villejuif, France
| | - Fawzia Louache
- Paris-Saclay University, UMRS-1170, Gustave Roussy, Villejuif, France.,CNRS GDR 3697 MicroNiT, France
| | - Monika Wittner
- Paris-Saclay University, UMRS-1170, Gustave Roussy, Villejuif, France.,CNRS GDR 3697 MicroNiT, France
| |
Collapse
|
22
|
Herault O, Vignon C, Debeissat C, Rouleux-Bonnin F, Gyan E, Mazurier F, Gouilleux F, Domenech J. Abstract LB-334: The Nrf2-subcellular localization in human acute myeloblastic leukemic cells is regulated by the bone marrow mesenchymal stem/stromal cells. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-lb-334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND. The redox metabolism is a key actor in the pathophysiology of acute myeloblastic leukemia (AML). High level of reactive oxygen species (ROS) is observed in the leukemic bulk, whereas leukemic stem cells (LSCs) have a low level of ROS, and we reported that glutathione peroxydase 3 (GPx-3) promotes competitiveness of LSCs in which Gpx3 overexpression is associated with a decreased level of ROS and inactivation of p38 MAPK (Herault O et al, J Exp Med 2012, 209:895).
NF-E2-related factor 2 (Nrf2) transcription factor, the master regulator of antioxidant responses, is highly expressed in acute myeloblastic leukemia (AML) and is involved in its chemoresistance (Rushworth SA et al, Blood 2012, 120,5188). Since leukemic cells interact with mesenchymal stem/stromal cells (MSCs) in the bone marrow (BM) niche, the aim of our study was to evaluate the effects of MSC-contact on the Nrf2 sub-cellular localization in acute myeloid leukemia (AML) cells and to concomitantly assess the the GPx-3/ROS/p38 MAPK axis and cell cycle status.
METHODS. BM MSCs (from consenting patients undergoing orthopaedic surgery) were used at P2. The mesenchymal differentiation capacity was systematically checked. The KG1a (FAB M0 AML) cell line and primary AML blasts were cultured for 72h in presence of MSCs and compared to their counterpart cultured in presence of supernatant from MSCs alone or medium alone. ROS level measurements (DCFDA), cell cycle analyses (Vignon C et al, PLOS One 2013, 8: e68425) and proliferation assays (CFSE) of the leukaemic cells were performed by flow cytometry. Expression levels of 24 key antioxidant genes, CDKN1A (p21, Cip1) and 22 Nrf2-regulated genes were quantified by qRT-PCR. Western-blot analyses were also realized to determine the expression levels of GPx-3 and p21(Cip1), the activation of p38 MAPK (T180/Y182) and the localization of Nrf2 after subcellular fractionation.
RESULTS. Adherent KG1a cells were characterized by major decrease in nuclear translocation of Nrf2 and expression of Nrf2-regulated genes. We concomitantly observed overexpression of GPX3 mRNA and protein, major decrease in ROS levels and inactivation of p38 MAPK. Similar results were obtained with adherent primary leukemic cells. These effects were concomitantly observed with major decrease in nuclear translocation of Nrf2 and expression of Nrf2-regulated genes. Interestingly, the increased G0 phase, together with the decreased S and M phases, and overexpression of CDKN1A mRNA and protein demonstrated cell cycle inhibition and reduced mitotic activity. The supernatant of MSCs did not impact on Nrf2-subcellular localization, GPx-3 expression and ROS levels in leukemic cells.
CONCLUSION. Altogether these findings suggest that the niche (direct contact to MSCs) plays a key role in the regulation of the oxidative metabolism in leukemic cells by modifying the subcellular localization of Nrf2 and by promoting the inhibition of the ROS/p38 MAPK axis through the induction of GPx-3, resulting in a reduced proliferation. Targeting the Nrf2 pathway in leukemic cells by a modulation of microenvironmental interactions may be a clinically relevant chemosensitizing approach.
Citation Format: Olivier Herault, Christine Vignon, Christelle Debeissat, Florence Rouleux-Bonnin, Emmanuel Gyan, Frederic Mazurier, Fabrice Gouilleux, Jorge Domenech. The Nrf2-subcellular localization in human acute myeloblastic leukemic cells is regulated by the bone marrow mesenchymal stem/stromal cells. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr LB-334.
Collapse
|
23
|
Guilleminault L, Azzopardi N, Arnoult C, Sobilo J, Hervé V, Montharu J, Guillon A, Andres C, Herault O, Le Pape A, Diot P, Lemarié E, Paintaud G, Gouilleux-Gruart V, Heuzé-Vourc'h N. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. J Control Release 2014; 196:344-54. [DOI: 10.1016/j.jconrel.2014.10.003] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2014] [Revised: 09/30/2014] [Accepted: 10/02/2014] [Indexed: 12/18/2022]
|
24
|
Vignon C, Debeissat C, Georget MT, Bouscary D, Gyan E, Rosset P, Herault O. Flow cytometric quantification of all phases of the cell cycle and apoptosis in a two-color fluorescence plot. PLoS One 2013; 8:e68425. [PMID: 23935867 PMCID: PMC3728345 DOI: 10.1371/journal.pone.0068425] [Citation(s) in RCA: 70] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2013] [Accepted: 05/29/2013] [Indexed: 11/19/2022] Open
Abstract
An optimal technology for cell cycle analysis would allow the concomitant measurement of apoptosis, G0, G1, S, G2 and M phases in combination with cell surface phenotyping. We have developed an easy method in flow cytometry allowing this discrimination in an only two-color fluorescent plot. It is based on the concomitant use of 7-amino-actinomycin D and the antibodies anti-Ki67 and anti-phospho(Ser10)-histone H3, both conjugated to Alexa Fluor®488 to discriminate G0 and M phases, respectively. The method is particularly valuable in a clinical setting as verified in our laboratory by analyzing human leukemic cells from marrow samples or after exposure to cell cycle modifiers.
Collapse
Affiliation(s)
- Christine Vignon
- Université François-Rabelais de Tours, Tours, France
- CNRS, UMR 7292, LNOx team, Tours, France
| | | | | | - Didier Bouscary
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, Paris, France
| | - Emmanuel Gyan
- Université François-Rabelais de Tours, Tours, France
- CNRS, UMR 7292, LNOx team, Tours, France
- CHRU de Tours, Service d’Hématologie Clinique et Thérapie Cellulaire, Tours, France
| | - Philippe Rosset
- CHRU de Tours, Service de Chirurgie Orthopédique et Traumatologique, Tours, France
| | - Olivier Herault
- Université François-Rabelais de Tours, Tours, France
- CNRS, UMR 7292, LNOx team, Tours, France
- CHRU de Tours, Service d’Hématologie Biologique, Tours, France
- * E-mail:
| |
Collapse
|
25
|
Herault O, Hope KJ, Deneault E, Mayotte N, Chagraoui J, Wilhelm BT, Cellot S, Sauvageau M, Andrade-Navarro MA, Hébert J, Sauvageau G. A role for GPx3 in activity of normal and leukemia stem cells. ACTA ACUST UNITED AC 2012; 209:895-901. [PMID: 22508837 PMCID: PMC3348115 DOI: 10.1084/jem.20102386] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
High levels of glutathione peroxidase 3 (GPx3) expression correlate with adverse prognosis in acute myeloid leukemia, and enhance activity of long-term repopulating hematopoietic stem cells in mice. The determinants of normal and leukemic stem cell self-renewal remain poorly characterized. We report that expression of the reactive oxygen species (ROS) scavenger glutathione peroxidase 3 (GPx3) positively correlates with the frequency of leukemia stem cells (LSCs) in Hoxa9+Meis1-induced leukemias. Compared with a leukemia with a low frequency of LSCs, a leukemia with a high frequency of LSCs showed hypomethylation of the Gpx3 promoter region, and expressed high levels of Gpx3 and low levels of ROS. LSCs and normal hematopoietic stem cells (HSCs) engineered to express Gpx3 short hairpin RNA (shRNA) were much less competitive in vivo than control cells. However, progenitor cell proliferation and differentiation was not affected by Gpx3 shRNA. Consistent with this, HSCs overexpressing Gpx3 were significantly more competitive than control cells in long-term repopulation experiments, and overexpression of the self-renewal genes Prdm16 or Hoxb4 boosted Gpx3 expression. In human primary acute myeloid leukemia samples, GPX3 expression level directly correlated with adverse prognostic outcome, revealing a potential novel target for the eradication of LSCs.
Collapse
Affiliation(s)
- Olivier Herault
- Institute for Research in Immunology and Cancer, University of Montreal, Montreal, Quebec, Canada
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, Bouscary D. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 2010; 16:5424-35. [PMID: 20884625 DOI: 10.1158/1078-0432.ccr-10-1102] [Citation(s) in RCA: 131] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
PURPOSE The growth and survival of acute myeloid leukemia (AML) cells are enhanced by the deregulation of signaling pathways such as phosphoinositide 3-kinase (PI3K)/Akt and mammalian target of rapamycin (mTOR). Major efforts have thus been made to develop molecules targeting these activated pathways. The mTOR serine/threonine kinase belongs to two separate complexes: mTORC1 and mTORC2. The mTORC1 pathway is rapamycin sensitive and controls protein translation through the phosphorylation of 4E-BP1 in most models. In AML, however, the translation process is deregulated and rapamycin resistant. Furthermore, the activity of PI3K/Akt and mTOR is closely related, as mTORC2 activates the oncogenic kinase Akt. We therefore tested, in this study, the antileukemic activity of the dual PI3K/mTOR ATP-competitive inhibitor NVP-BEZ235 compound (Novartis). EXPERIMENTAL DESIGN The activity of NVP-BEZ235 was tested in primary AML samples (n = 21) and human leukemic cell lines. The different signaling pathways were analyzed by Western blotting. The cap-dependent mRNA translation was studied by 7-methyl-GTP pull-down experiments, polysomal analysis, and [(3)H]leucine incorporation assays. The antileukemic activity of NVP-BEZ235 was tested by analyzing its effects on leukemic progenitor clonogenicity, blast cell proliferation, and survival. RESULTS The NVP-BEZ235 compound was found to inhibit PI3K and mTORC1 signaling and also mTORC2 activity. Furthermore, NVP-BEZ235 fully inhibits the rapamycin-resistant phosphorylation of 4E-BP1, resulting in a marked inhibition of protein translation in AML cells. Hence, NVP-BEZ235 reduces the proliferation rate and induces an important apoptotic response in AML cells without affecting normal CD34(+) survival. CONCLUSIONS Our results clearly show the antileukemic efficiency of the NVP-BEZ235 compound, which therefore represents a promising option for future AML therapies.
Collapse
Affiliation(s)
- Nicolas Chapuis
- Institut Cochin, Université Paris Descartes, CNRS (UMR8104)/INSERM U1016; Service d'Hématologie Biologique, Hôpital Cochin, AP-HP, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Gallay N, Anani L, Lopez A, Colombat P, Binet C, Domenech J, Weksler BB, Malavasi F, Herault O. The Role of Platelet/Endothelial Cell Adhesion Molecule–1 (CD31) and CD38 Antigens in Marrow Microenvironmental Retention of Acute Myelogenous Leukemia Cells. Cancer Res 2007; 67:8624-32. [PMID: 17875702 DOI: 10.1158/0008-5472.can-07-0402] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
In acute myelogenous leukemia (AML), leukemic cell-microenvironment interactions within various niches (stromal/osteoblastic or sinusoidal endothelial cell niches) have a role in leukemia cell survival and drug resistance. The AML leukemic cells express platelet/endothelial cell adhesion molecule-1 (CD31) and CD38, two adhesion molecules that could interact with microenvironmental elements, i.e., CD31 on the surface of marrow endothelial cells (CD31/CD31 and CD38/CD31 interactions) and hyaluronate (CD38/hyaluronate interactions). We report a physical association of these two antigens on the plasma membrane of myeloid leukemic cells. In this context, in vitro experiments done using interaction-blocking anti-CD31 and anti-CD38 monoclonal antibodies (CLB-HEC75 and OKT10, respectively) indicate that an excess of CD31 on the cell membrane of leukemic cells (CD31/CD38 MFI ratio >1) promotes a homotypic interaction with marrow endothelial cells, resulting in higher transendothelial migration. Conversely, an excess of CD38 (CD31/CD38 MFI ratio <1) allows leukemic cells to be entrapped within the bone marrow microenvironment through hyaluronate adhesion. The results obtained in vitro using fluorescence resonance energy transfer, co-capping, and co-immunoprecipitation experiments, and hyaluronate adhesion and transendothelial migration assays, are supported by immunophenotypic characterization of marrow leukemic cells from 78 AML patients on which CD38 expression levels were found to be positively correlated with those of CD31. Importantly, the excess of CD31 in those samples was associated with a higher peripheral WBC count. These findings indicate that bone marrow retention of AML cells depends on CD31 and CD38 coexpression levels.
Collapse
MESH Headings
- ADP-ribosyl Cyclase 1/immunology
- ADP-ribosyl Cyclase 1/metabolism
- Adolescent
- Adult
- Aged
- Antibodies, Monoclonal/immunology
- Antibodies, Monoclonal/pharmacology
- Bone Marrow Cells/immunology
- Bone Marrow Cells/metabolism
- Bone Marrow Cells/pathology
- Cell Adhesion/physiology
- Cell Membrane/metabolism
- Cell Movement/physiology
- Endothelial Cells/immunology
- Endothelial Cells/metabolism
- Endothelial Cells/pathology
- Fluorescence Resonance Energy Transfer
- HL-60 Cells
- Humans
- Hyaluronic Acid
- Immunophenotyping
- Leukemia, Myeloid, Acute/blood
- Leukemia, Myeloid, Acute/immunology
- Leukemia, Myeloid, Acute/metabolism
- Leukemia, Myeloid, Acute/pathology
- Leukocyte Count
- Middle Aged
- Platelet Endothelial Cell Adhesion Molecule-1/immunology
- Platelet Endothelial Cell Adhesion Molecule-1/metabolism
- U937 Cells
Collapse
Affiliation(s)
- Nathalie Gallay
- INSERM ESPRI-EA3855, Université François Rabelais, Tours, France
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Abstract
The iron deficiency is the first cause of anaemia. In healthy young adult, anemia is well tolerated because of its progressive installation. The most common symptoms of anemia are pallor, fatigue and dyspnea. In biological exams, anemia is classically associated with microcytosis and hypochromia. The origins of microcytic anemia are iron deficiency, inflammatory aetiologies, thalassemia and sideroblastic anaemia. The iron-deficiency diagnosis includes two explorations: biological and clinical. The biological exploration is based on interpretation of serum biologics tests as blood iron, ferritin, transferrin with saturation, total iron-binding capacity and its soluble receptors. This interpretation is simple if it is not associated with clinical disorders influencing the internal iron cycle. The clinical exploration must always be followed by a careful assessment of the underlying cause as blood loss. The most common causes in women of reproductive age are gynaecologic. In men and menopausal women, the gastrointestinal tract bleeding is source of anemia. Therapeutic management of anemia is oral iron therapy. Etiological diagnostic of microcytosis is essential before iron therapy. If not, the treatment could be inefficient or it could mask or delay the etiological diagnostic.
Collapse
Affiliation(s)
- C Espanel
- Service d'hématologie, hôpital Bretonneau, CHRU de Tours, 2 boulevard Tonnellé, 37044 Tours cedex 9, France.
| | | | | | | | | | | |
Collapse
|
29
|
Guillard J, Decrop M, Gallay N, Espanel C, Boissier E, Herault O, Viaud-Massuard MC. Synthesis and biological evaluation of 7-azaindole derivatives, synthetic cytokinin analogues. Bioorg Med Chem Lett 2007; 17:1934-7. [PMID: 17300934 DOI: 10.1016/j.bmcl.2007.01.033] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2006] [Revised: 01/09/2007] [Accepted: 01/10/2007] [Indexed: 10/23/2022]
Abstract
Cytokinins, N6-substituted adenine derivatives, are plant hormones playing important roles in various processes in plant development. Furthermore, cytokinins and their derivatives are able to control mammalian cell apoptosis and differentiation. The aim of our study was the synthesis of 7-azaindole derivatives as cytokinin analogues with the Hartwig-Buchwald coupling reaction in order to evaluate their biological properties on human myeloblastic leukaemia cells (HL-60 cell line). All these compounds presented a cytotoxic activity on HL-60 cells especially the 4-phenylaminopyrrolo[2,3-b]pyridine and the 4-phenethylaminopyrrolo[2,3-b]pyridine.
Collapse
Affiliation(s)
- Jérome Guillard
- SPOT-EA3857, UFR des Sciences Pharmaceutiques, 31 Avenue Monge, 37200 Tours, France
| | | | | | | | | | | | | |
Collapse
|
30
|
|
31
|
Dommange F, Cartron G, Espanel C, Gallay N, Domenech J, Benboubker L, Ohresser M, Colombat P, Binet C, Watier H, Herault O. CXCL12
polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia. FASEB J 2006; 20:1913-5. [PMID: 16818471 DOI: 10.1096/fj.05-5667fje] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Stromal cell-derived factor 1 (SDF-1), a chemokine abundantly produced by the bone marrow microenvironment, and its receptor CXCR4 have crucial roles in malignant cell trafficking. In acute myeloid leukemia (AML), blasts invade the bloodstream and may localize in extramedullar sites, with variations from one patient to another. We hypothesized that a polymorphism in the SDF-1 coding gene (CXCL12 G801A) could influence blast dissemination and tissue infiltration in AML. CXCL12 G801A polymorphism was determined in 86 adult patients and 100 healthy volunteers. The allelic status and CXCR4 expression on bone marrow blasts were analyzed in relation to peripheral blood blast (PBB) counts and frequency of extramedullar tumor sites. 801A carrier status (801G/A, 801A/A) was found to be associated with a higher PBB count compared with 801G/G homozygous patients (P=0.031) and higher frequency of extramedullar tumor sites (odds ratio 2.92, 95% confidence interval 1.18-7.21, P=0.018). Moreover, the PBB count was correlated with CXCR4 expression (correlation coefficient 0.546, P=0.001) when considering 801A carriers. In conclusion, a polymorphism in the SDF-1 gene is shown for the first time to be associated with the clinical presentation of a malignant hematological disease and more generally with the risk of distant tissue infiltration by tumor cells.
Collapse
Affiliation(s)
- Florence Dommange
- CHRU de Tours, Laboratoire d'Hématologie, Service d;Hématologie et Thérapie Cellulaire
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Herault O, Gallay N, Domenech J, Colombat P, Binet C. Pharmacological doses of all-trans retinoic acid promote G0/G1 transition and G1 arrest of normal human marrow CD34+ cells. Cell Death Differ 2005; 11 Suppl 2:S207-9. [PMID: 15309027 DOI: 10.1038/sj.cdd.4401471] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
|
33
|
Brossay A, Harang S, Herault O, Bardos P, Watier H. The active role played by xenogeneic endothelial cells in the indirect presentation pathway is not lymphocyte trans-co-stimulation. Transpl Int 2004. [DOI: 10.1111/j.1432-2277.2004.tb00512.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Herault O, Domenech J, Georget MT, Clement N, Colombat P, Binet C. All-trans retinoic acid prevents apoptosis of human marrow CD34+ cells deprived of haematopoietic growth factors. Br J Haematol 2002; 118:289-95. [PMID: 12100164 DOI: 10.1046/j.1365-2141.2002.03573.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The regulation of apoptosis plays a key role in haematopoiesis. It has been demonstrated that haematopoietic progenitor cells progressively undergo apoptotic cell death in the absence of appropriate growth factors. We studied the effects of pharmacological doses of all-transretinoic acid (ATRA) on the apoptosis of human adult marrow CD34+ progenitor cells cultured for 7 d in a serum-free medium. We quantified CD34+ cells, clonogenic progenitors and 5 week colony-forming cells (CFC) before and after ATRA exposure. Moreover, we defined the apoptotic status of the CD34+ cell fraction by analysis of phosphatidylserine externalization (using annexin V), the relative membrane permeability to 7-aminoactinomycin D (7AAD) and the mitochondrial membrane potential [using 3,3'-dihexyloxacarbocyanine iodide, DiOC6(3)]. In the drastic experimental conditions used, a decrease in viable CD34+ cells, granulocyte-macrophage colony-forming units (CFU-GM), erythroid burst-forming units (BFU-E) and 5 week CFC were observed. Exposure to ATRA partially prevented the decrease in viable CD34+, without a concomitant effect on the clonogenic and more immature progenitors. ATRA-treated CD34+ cells displayed changes in apoptotic status compared with control cultures, particularly in lower annexin V-binding. These results were confirmed using 7AAD and DiOC6(3). Our results demonstrate that ATRA exerts a protective effect on CD34+ cells exposed to such apoptotic stress.
Collapse
Affiliation(s)
- Olivier Herault
- EA-3249 'Cellules Hématopoïétiques, Hémostase et Greffe' Faculty of Medicine, University Hospital, Tours, France.
| | | | | | | | | | | |
Collapse
|
35
|
Domenech J, Cartron G, Clement N, Estienne MH, Herault O, Truglio D, Benboubker L, Roingeard F, Desbois I, Colombat P, Binet C. Persistent decrease in proliferative potential of marrow CD34(+)cells exposed to early-acting growth factors after autologous bone marrow transplantation. Bone Marrow Transplant 2002; 29:557-62. [PMID: 11979303 DOI: 10.1038/sj.bmt.1703512] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2001] [Accepted: 01/04/2002] [Indexed: 11/09/2022]
Abstract
Post-graft hematopoiesis is characterized by long-term quantitative deficiency in marrow progenitor cells in both autologous and allogenic settings. In order to evaluate the function of post-graft progenitor cells, the proliferative capacity of marrow CD34(+) cells was evaluated in 10 patients 6 months after autologous bone marrow transplantation (ABMT) for non-Hodgkin's lymphoma and compared to that of 10 patients before ABMT and 10 normal controls. Immuno-selected CD34(+) cells were cultured for 7 days in liquid serum-free medium with a combination of early-acting GF consisting of stem cell factor, IL-3 and IL-1beta. Clonogenic efficiency of unselected cells for CFU-GM and BFU-E was decreased in post-graft patients compared to pre-graft and control patients. However, clonogenic efficiency of selected CD34(+) cells for CFU-GM was not different in post-graft, pre-graft and control patients but BFU-E values of post-graft patients remained lower than those of control patients. Decreased percentages of CD34(+) CD38(-) cells were observed in both post-graft and pre-graft patients while those of CD34(+) c-kit(+) cells were similar in all three patient groups. After 7-day liquid culture, expansion yields of total progenitor cells were significantly lower in post-graft patients (147 +/- 28%) than in pre-graft (255 +/- 27%) and control patients (246 +/- 23%). Post-graft deficiency in progenitor cell expansion was particularly marked for BFU-E (61 +/- 24%) compared to pre-graft patients (220 +/- 82%) and to controls (349 +/- 82%). These results indicate impaired proliferative potential of marrow CD34(+) cells several months after ABMT involving erythroid progenitor cells and/or commitment towards erythroid lineage from a more immature stage (pre-CFU).
Collapse
Affiliation(s)
- J Domenech
- UPRES-EA 3249, Laboratory of Hematology, University Hospital of Tours, Tours, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Cartron G, Herault O, Benboubker L, Clement N, Bernard MC, Roingeard F, Desbois I, Colombat P, Binet C, Domenech J. Quantitative and qualitative analysis of the human primitive progenitor cell compartment after autologous stem cell transplantation. J Hematother Stem Cell Res 2002; 11:359-68. [PMID: 11983107 DOI: 10.1089/152581602753658547] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The aim of this study was to examine whether the severe prolonged deficiency in marrow clonogenic progenitor cells reported after autologous stem cell transplantation (ASCT) is associated with impairment of the primitive progenitor cell compartment. We performed Dexter-type marrow cultures and limiting dilution assays with CD34(+) cells from patients 1 year and/or later after autografting with peripheral blood stem cells for non-Hodgkin's lymphoma (NHL). Flow cytometric analysis was used to assess the CD38 antigen expression and apoptotic state (7-ADD(-)/annexin-V(+) cells) of the CD34(+) cell population. We found a dramatic decrease in both clonogenic progenitor cell production and frequency of long term culture-initiating cells (LTC-IC) in all the patients tested at 1 year, even in those displaying normal progenitor cell frequency. Surprisingly, the clonogenic capacity of each LTC-IC was not increased. Flow cytometric analysis of the CD34(+) cell population confirmed this quantitative defect, with a reduction in the CD38(dim/neg) cell population but no increase in apoptosis. This defect did not improve over time up to 4 years after transplantation. In addition, qualitative abnormalities were revealed, demonstrated by decreased CD34 antigen expression, together with impaired differentiating properties of LTC-IC toward erythroid lineage at 1 year. This study indicates that both quantitative and qualitative abnormalities of the primitive progenitor cell compartment are a constant feature up to 4 years after autologous stem cell transplantation.
Collapse
Affiliation(s)
- Guillaume Cartron
- Laboratory of Hematology and Department of Medical Oncology and Blood Diseases, University Hospital, Tours, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Pouplard C, Iochmann S, Renard B, Herault O, Colombat P, Amiral J, Gruel Y. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001; 97:3300-2. [PMID: 11342462 DOI: 10.1182/blood.v97.10.3300] [Citation(s) in RCA: 154] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The pathogenesis of thrombosis in heparin-induced thrombocytopenia (HIT) was studied by investigating whether antibodies to heparin-platelet factor 4 (H-PF4) induced tissue factor (TF) synthesis by monocytes. Plasma from 5 patients with HIT containing IgG to H-PF4 was incubated with peripheral blood mononuclear cells without or with purified PF4 and heparin. Significant TF-dependent procoagulant activity (PCA) expressed by monocytes, measured with a factor Xa-based chromogenic assay, was induced after incubation of each HIT plasma sample. This monocyte PCA required the presence of PF4 and was inhibited by high concentrations of heparin. Furthermore, purified HIT IgG added to whole blood with PF4 and heparin also provoked significant synthesis of TF mRNA by monocytes, demonstrated by RT-PCR, and this effect was not observed with normal IgG. These findings strongly support the hypothesis that antibodies to PF4 developed in HIT trigger the production of tissue factor by monocytes, and this effect could account in vivo for hypercoagulability and thrombotic complications in affected patients.
Collapse
Affiliation(s)
- C Pouplard
- Department of Hematology, Faculté de Médecine, Tours, and Hyphen Biomed, Andresy, France
| | | | | | | | | | | | | |
Collapse
|
38
|
Benboubker L, Watier H, Domenech J, Carion A, Cartron G, Georget M, Herault O, Desbois I, Delain M, Bardos P, Colombat P, Binet C. Levels of CD34+ progenitor cells mobilized into peripheral blood are associated with SDF1 Gene variants. Exp Hematol 2000. [DOI: 10.1016/s0301-472x(00)00245-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
39
|
Herault O, Colombat P, Domenech J, Degenne M, Bremond JL, Sensebe L, Bernard MC, Binet C. A rapid single-laser flow cytometric method for discrimination of early apoptotic cells in a heterogenous cell population. Br J Haematol 1999; 104:530-7. [PMID: 10086791 DOI: 10.1046/j.1365-2141.1999.01203.x] [Citation(s) in RCA: 68] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
A recently reported cytometric method described the possibility of discriminating apoptotic from necrotic cells using FITC-labelled annexin V and propidium iodide (PI). Nevertheless, the brightness of PI-staining and its extensive spectral emission overlap with phycoerythrin (PE) does not permit the study of a subset of a heterogenous cell population with single laser instrumentation. The surface staining of a subset with PE in a heterogenous cell population therefore requires another exclusion dye to detect necrotic cells. We used 7-amino-actinomycin D (7-AAD) that can be excited by the 488 nm argon laser line. 7-AAD emits in the far red range of the spectrum and 7-AAD spectral emission can be separated from the emissions of FITC and PE. The fluorescence parameters allow characterization of necrotic (7-AAD+ annexin V-FITC+ cells), apoptotic (7-AAD-annexin V-FITC+ cells) and viable cells (7-AAD- annexin V-FITC- cells) in a subset of PE+ cells. The value of this method was demonstrated by measuring apoptosis and necrosis in a model of HL-60 cells exposed to different inducers of cell death. The method was validated by fluorescent cell sorting in combination with morphologic examination of the sorted cells. The technique we present is particularly valuable in a clinical setting because it enables rapid multiparameter analysis of necrosis and early apoptosis in combination with cell surface phenotyping with a single laser. We present the effects of haemopoietic growth factor deprivation on myeloid progenitor CD34+ cells as an example of its application.
Collapse
Affiliation(s)
- O Herault
- Faculty of Medicine, Laboratory of Haematology, Tours, France
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Herault O, Domenech J, Degenne M, Bremond JL, Sensebe L, Bernard MC, Binet C, Colombat P. All-trans-retinoic acid up-regulates CD38 but not c-Kit antigens on human marrow CD34+ cells without recruitment into cell cycle. Br J Haematol 1998; 103:343-50. [PMID: 9827903 DOI: 10.1046/j.1365-2141.1998.01015.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Retinoids, especially all-trans-retinoic acid (ATRA), are well known for their differentiating activity on HL-60 cells. Moreover ATRA induces CD38 antigen overexpression on these cells. In this study we examined the effects of ATRA on purified normal CD34+ cells from adult human marrows incubated with ATRA (1 microM) or stem cell factor (SCF) after 7 d liquid cultures in serum-deprived medium. Before and after the incubation, CD34+ cells were studied by flow cytometry to evaluate the cell-surface expression of CD38 and c-Kit antigens and the cycle status of these cells using high-resolution analysis (DNA content v Ki-67 antigen expression) to clarify the functional meaning of antigenic variations. When compared with control cultures, ATRA-treated cells displayed changes in their immunophenotypic profile. Particularly relevant was the up-regulation of CD38 antigen with a mean (+/-SEM) fold increase of 21 +/- 0.1 (P=0.028) for geometric mean fluorescence intensity (GMFI), without modulation of c-Kit expression. SCF only down-regulated expression of c-Kit with a fold decrease of 4.6 +/- 0.9 for GMFI (P=0.043). Unlike SCF, ATRA did not induce CD34+ cells to entry into cell cycle despite increased levels of surface CD38 antigen. Moreover morphological and functional assays did not argue for an ATRA-induced maturation process. Contrary to steady-state cells, CD34+ cells treated with pharmacological doses of ATRA alone displayed CD38 over-expression without change in c-Kit levels and cycle status, suggesting an absence of maturation pressure.
Collapse
Affiliation(s)
- O Herault
- JE 1993, Faculty of Medicine, Tours, France
| | | | | | | | | | | | | | | |
Collapse
|